BTK inhibitors

By providing a compound of a specific structure or its salt, effective inhibition of Bruton's tyrosine kinase is solved, and the problem of difficulty in inhibiting Btk enzyme in the prior art is provided, and a potential treatment plan for autoimmune diseases and other related diseases is provided.

CN118984829APending Publication Date: 2024-11-19BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280080312.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2021-11-12
Filing Date
2022-11-11
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit Bruton's tyrosine kinase (Btk), which plays an important role in B cell signaling, and challenges exist in the treatment of related diseases such as primary immunodeficiency XLA syndrome and autoimmune disorders.

Method used

A compound, specifically structured as a compound containing a specific heterocyclic ring and halogen group or a pharmaceutically acceptable salt thereof, is provided for inhibiting the activity of the Btk enzyme for the treatment of related conditions.

Benefits of technology

This compound or its salt can effectively inhibit Btk enzymes and is potentially used to treat autoimmune diseases, inflammatory conditions and certain cancers, providing a new therapeutic strategy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118984829A_ABST
    Figure CN118984829A_ABST
Patent Text Reader

Abstract

Provided are compounds of Formula (I): # imgabs0 # or a pharmaceutically acceptable salt thereof, wherein the variables in Formula (I) are as defined herein; and methods of use and preparation thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims the benefit of the filing date of U.S. Provisional Application No. 63 / 278,718, filed on November 12, 2021, under 35 U.S.C. §119(e), the entire contents of which are incorporated herein by reference. Technical Field

[0003] Certain agents that inhibit Bruton's tyrosine kinase (Btk), as well as methods of making and using such agents, are provided. Background Art

[0004] Protein kinases are a large gene family consisting of more than 500 proteins that play key roles in the development and treatment of many human diseases in oncology, neurology, and immunology.

[0005] Tec kinase is a non-receptor tyrosine kinase consisting of five members (Tec (tyrosine kinase expressed in hepatocellular carcinoma), Btk (Bruton's tyrosine kinase), Itk (interleukin-2 (IL-2)-inducible T-cell kinase; also known as Emt or Tsk), Rlk (resting lymphocyte kinase; also known as Txk), and Bmx (myeloid tyrosine kinase gene on chromosome X; also known as Etk)) and is mainly expressed in hematopoietic cells, although expression of Bmx and Tec has been detected in endothelial cells and hepatocytes. Tec kinases (Itk, Rlk, and Tec) are expressed in T cells and are all activated downstream of the T cell receptor (TCR). Btk is a downstream mediator of B cell receptor (BCR) signaling and is involved in regulating B cell activation, proliferation, and differentiation. More specifically, Btk contains a PH domain that binds phosphatidylinositol (3,4,5)-triphosphate (PIP3). PIP3 binding induces Btk to phosphorylate phospholipase C (PLCy), which in turn hydrolyzes PIP2 to produce two second messengers: inositol triphosphate (IP3) and diacylglycerol (DAG), which activate protein kinase PKC, which then induces additional B cell signaling. Mutations that inactivate the Btk enzyme cause the primary immunodeficiency XLA syndrome (X-linked agammaglobulinemia). Given the key role played by Tec kinases in B cell and T cell signaling, Tec kinases are targets of interest for autoimmune disorders.

[0006] Given the important role that Btk plays in B cell signaling, there is a great need in the art for effective Btk inhibitors. Summary of the invention

[0007] One aspect of the present disclosure is a compound of formula (I):

[0008]

[0009] or a pharmaceutically acceptable salt thereof, wherein:

[0010] X 0 N, X 1 C, X 2 is N and X 4 N; X 0 CR 0 , X 1 C, X 2 is N and X 4 N; X 0 CR 0 , X 1 N, X 2 is C and X 4 N; X 0 CR 0 , X 1 N, X 2 is C and X 4 is CH; or X 0 CR 0 , X 1 C, X 2 is N and X 4 for CH;

[0011] R 0 is H, halo, -CH3, halomethyl, cyclopropyl or CN;

[0012] Het is phenyl, 5-6 membered heteroaryl or N-(C1-C1 alkyl)pyridinone;

[0013] R 1 is H or C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C3-C6 cycloalkyl or 4-7 membered monocyclic oxygen-containing heterocycle;

[0014] X 3 Does not exist, -S-, -SO2-, CR 3a R 3b , -C(=O)- or -(C=O)-NH-*, where * indicates connection to R 2 point;

[0015] R 3a and R 3b Each independently is H or halogen, wherein R 3a and R 3b At least one of is not H;

[0016] When X 3 Does not exist, -S-, -SO2-, CR 3a R 3b or -(C=O)-NH-*, R 2 is bonded to X through a ring carbon atom 3 ("C-linked") 4-12 membered monocyclic or bicyclic nitrogen-containing heterocyclic ring, bonded to X via a ring nitrogen atom 3 ("N-linked") 8-12 membered bicyclic nitrogen-containing heterocycle, 4-7 membered monocyclic oxygen-containing heterocycle, phenyl or 3-12 membered monocyclic or bicyclic carbocyclic group, wherein R 2 The 4-7 membered monocyclic oxygen-containing heterocyclic ring, phenyl group and 3-12 membered monocyclic or bicyclic carbon ring group represented by R are each represented by 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R 2 The C-linked 4-12-membered monocyclic or bicyclic nitrogen-containing heterocyclic ring represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 and substituted by a group represented by R 2 The N-linked 8-12-membered bicyclic nitrogen-containing heterocycle represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted;

[0017] When X 3 When it does not exist, R 2 It can also be represented by formula (A):

[0018]

[0019] When X 3 When -C(=O)-, R2 is bonded to X through a ring nitrogen atom. 3 ("N-linked"), a 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle, a 4-7 membered monocyclic oxygen-containing heterocycle, a phenyl group, or a 3-12 membered monocyclic or bicyclic carbocyclic group, wherein R 2 The 4-7 membered monocyclic oxygen-containing heterocyclic ring, phenyl group and 3-12 membered monocyclic or bicyclic carbon ring group represented by R are each represented by 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R 2 The N-linked 4-12-membered monocyclic or bicyclic nitrogen-containing heterocyclic ring represented by R 4 A group represented by R is C-substituted and optionally further substituted with one or two 10 The group represented by is substituted;

[0020] R4 for

[0021]

[0022] R 5 for

[0023]

[0024] R 6 is H, C1-C3 alkyl, C1-C3 haloalkyl, N(R a )2 or CH2N(R a )2, where each R a are independently H or methyl;

[0025] R 6’ is H, C1-C3 alkyl or C1-C3 haloalkyl;

[0026] R 7 is H, C1-C2 alkyl or C1-C2 fluoroalkyl;

[0027] Each R 10 Independently F or C 1-3 alkyl;

[0028] R 11 H or N(R 12 )2;

[0029] Each R 12 are independently H or C1-C3 alkyl;

[0030] R 13 CN or F;

[0031] n is 0 or 1;

[0032] p is 1 or 2; and

[0033] q is 1 or 2.

[0034] In a second aspect, the present disclosure provides a pharmaceutical composition comprising at least one compound described herein or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient.

[0035] In a third aspect, the present disclosure provides a method of treating a condition responsive to Bruton's tyrosine kinase (Btk) inhibition in a subject. The method comprises administering to the subject an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof.

[0036] The present disclosure also includes the use of at least one compound described herein or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating a condition responsive to Btk inhibition. Also provided is a compound described herein or a pharmaceutically acceptable salt thereof for treating a condition responsive to Btk inhibition.

[0037] Other features or advantages will be apparent from the following detailed description of several embodiments, and from the appended claims. DETAILED DESCRIPTION

[0038] The compounds as described herein, or pharmaceutically acceptable salts thereof, may have activity as Btk modulators. Specifically, the compounds as described herein, or pharmaceutically acceptable salts thereof, may be Btk inhibitors.

[0039] I. Definitions

[0040] As used herein, the term "alkyl" refers to a fully saturated branched or unbranched chain hydrocarbon moiety. In some embodiments, the alkyl group contains 1 to 20 carbon atoms, 1 to 10 carbon atoms, 1 to 8 carbon atoms, 1 to 6 carbon atoms, or 1 to 4 carbon atoms. In some embodiments, the alkyl group contains 6 to 20 carbon atoms. Representative examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, or n-hexyl.

[0041] "Alkenyl" refers to an unsaturated hydrocarbon group that may be straight or branched and has at least one carbon-carbon double bond. In some embodiments, the alkenyl group has 2 to 20 carbon atoms, 2 to 10 carbon atoms, or 2-6 carbon atoms. The alkenyl group may contain 1, 2, or 3 or more carbon-carbon double bonds. Examples of alkenyl groups include vinyl, n-propenyl, isopropenyl, n-but-2-enyl, n-hex-3-enyl, etc.

[0042] "Alkynyl" refers to an unsaturated hydrocarbon group that may be straight or branched and has at least one carbon-carbon triple bond. In some embodiments, it may be preferred that the alkynyl group has 2 to 20 carbon atoms, 2 to 10 carbon atoms, or 2-6 carbon atoms. The alkynyl group may contain 1, 2, or 3 or more carbon-carbon triple bonds. Examples of alkynyl groups include ethynyl, n-propynyl, n-but-2-ynyl, n-hex-3-ynyl, etc.

[0043] As used herein, the term "alkoxy" refers to a fully saturated branched or unbranched chain alkyl moiety attached through an oxygen bridge (ie, --O--C 1-4 Alkyl, where C 1-4Alkyl is as defined herein). Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, and the like. In some embodiments, the alkoxy has about 1-4 carbons, more preferably about 1-2 carbons.

[0044] As used herein, the term "aryl" is defined to include all-carbon monocyclic or fused-ring polycyclic (i.e., rings that share adjacent pairs of carbon atoms) groups with a completely conjugated π electron system. Aryl groups may have 6, 8, 9, or 10 carbon atoms in one or more rings. In some embodiments, aryl groups may have 6 or 10 carbon atoms in one or more rings. For example, as used herein, the term "(C6-C 10 The "aryl" aromatic group contains 6 to 10 carbon atoms, such as phenyl, naphthyl, tetrahydronaphthyl, anthracenyl, indanyl, etc. The aryl group having 6 carbon atoms in one or more rings may be optionally substituted with 1 to 5 suitable substituents.

[0045] In some embodiments, the number of carbon atoms in a group is indicated herein by the prefix "C x-xx " or "C x -C xx ", where x and xx are integers. For example, "C 1-4 "Alkyl" or "C1-C4 alkyl" is an alkyl group having 1 to 4 carbon atoms.

[0046] As used herein, the term "carbocyclyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or bicyclic ring system (e.g., a fused, bridged, or spirocyclic ring system) having 4 to 12 ring members, all of which are carbon. The term "carbocyclyl" encompasses cycloalkyl and cycloalkenyl.

[0047] In one embodiment, the carbocyclyl is a 3- to 7-membered monocyclic carbocyclyl. Exemplary 3- to 7-membered monocyclic carbocyclyls include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclobutadienyl, cyclopentadienyl, cyclohexadienyl, cycloheptadienyl, phenyl, and cycloheptatrienyl.

[0048] In one embodiment, the carbocyclyl is a 7- to 10-membered bicyclic carbocyclyl. Exemplary 7- to 10-membered bicyclic carbocyclyls include, but are not limited to, bicyclo[2.1.1]hexyl, bicyclo[2.2.1]heptyl, bicyclo[2.2.1]heptenyl, 6,6-dimethylbicyclo[3.1.1]heptyl, 2,6,6-trimethylbicyclo[3.1.1]heptyl, spiro[3.3]heptyl, spiro[2.5]octyl, spiro[2.2]pentyl, spiro[3.3]heptyl, bicyclo[3.3.0]octyl, bicyclo[2.2.2]octyl, bicyclo[3.3.1]nonyl, bicyclo[3.3.2]decyl, decahydronaphthyl, naphthyl, and indanyl.

[0049] The fused bicyclic carbocyclic group has a 4- to 7-membered carbocyclic group fused to a 3- to 7-membered non-aromatic carbocyclic group. Examples include decahydronaphthalene, octahydro-1H-indene, octahydropentalene, octahydroazulene, decahydro-1H-annulene, bicyclo[4.2.0]octane, bicyclo[3.2.0]heptane, and the like.

[0050] Bridged bicyclic carbocyclyls comprise a non-aromatic 5- to 7-membered carbocyclyl group which shares three ring atoms with a 5- to 7-membered non-aromatic carbocyclyl group. Examples of bridged bicyclic carbocycles include bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl, and bicyclo[3.3.1]nonyl.

[0051] "Cycloalkyl" refers to a fully saturated monocyclic hydrocarbon group of 3-7 carbon atoms, including cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cyclopentyl; and "cycloalkenyl" refers to an unsaturated non-aromatic monocyclic hydrocarbon group of 3-7 carbon atoms, including cyclopenteneyl, cyclohexenyl and cyclopentenyl. The term "cycloalkyl" includes fully saturated monocyclic or bicyclic or spirocyclic hydrocarbon groups of 3-7 carbon atoms, 3-6 carbon atoms or 5-7 carbon atoms. In some embodiments, cycloalkyl is a 3-6-membered monocyclic cycloalkyl.

[0052] "Halogen" or "halo" may be fluorine, chlorine, bromine or iodine.

[0053] The term "haloalkyl" or "halo-substituted alkyl" refers to an alkyl group having at least one halogen substitution.

[0054] "Haloalkoxy" is a haloalkyl group attached to another moiety via an oxygen atom, such as, but not limited to, -OCHCF2 or -OCF3.

[0055] "Heteroaryl" refers to an aromatic 5- to 6-membered monocyclic ring system having 1 to 4 heteroatoms independently selected from O, N and S, and wherein N may be oxidized (e.g., N(O)) or quaternized, and S may be optionally oxidized to sulfoxide and sulfone. Examples of 5- to 6-membered monocyclic heteroaryls include, but are not limited to, pyrrolyl, furyl, thiophenyl (or thienyl), imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, furazolyl, oxadiazolyl, thiadiazolyl, dithiazolyl, triazolyl, tetrazolyl, pyridyl, pyranyl, thiopyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazinyl, thiazinyl, dioxinyl, dithiinyl, oxathiacyclohexane, triazinyl, tetrazinyl, etc. In one embodiment, heteroaryl is a 5-membered heteroaryl. Examples of 5-membered heteroaryl groups include, but are not limited to, pyrazolyl, oxazolyl, isoxazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, and tetrazolyl.

[0056] The terms "heterocyclyl" and "heterocycle" refer to a saturated or partially unsaturated monocyclic or bicyclic ring system (e.g., fused, bridged, or spirocyclic ring system) having 3 to 12 ring members, at least one of which is a heteroatom, and up to 4 (e.g., 1, 2, 3, or 4) of which may be heteroatoms, wherein heteroatoms are independently selected from O, S, and N, and wherein C may be oxidized (e.g., C(O)), N may be oxidized (e.g., N(O)) or quaternized, and S may be optionally oxidized to sulfoxide and sulfone. In some embodiments, the heterocyclyl is a 4- to 6-, 4- to 7-, or 3- to 7-membered monocyclic heterocycle. In some embodiments, the heterocyclyl is a 7- to 12-membered bicyclic heterocycle, which may be a fused, bridged, or spirobicyclic heterocycle. In some embodiments, the bicyclic heterocycle may include a non-aromatic heterocycle fused to a heteroaromatic ring.

[0057] Examples of monocyclic heterocycles include, but are not limited to, oxetanyl, thietanyl, azetidinyl, pyrrolidinyl, tetrahydrofuranyl, thiolanyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, dioxolanyl, dithiolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, morpholinyl, thiomorpholinyl, dioxanyl, dithianyl, trioxanyl, trithianyl, azepanyl, oxepanyl, thiepanyl, dihydrofuranyl, imidazolinyl, and dihydropyranyl.

[0058] Examples of bicyclic heterocycles include, but are not limited to, 9-azabicyclo[3.3.1]nonyl, 2-azabicyclo[2.2.2]octyl, 8-azabicyclo[3.2.1]octyl, 2,7-diazaspiro[4.4]nonane, octahydrocyclopenta[c]pyrrolyl, octahydro-1H-pyrrolo[3,4-c]pyridine.

[0059] A "fused ring system" has 8 to 12 members (ring atoms) and two rings that share two adjacent ring atoms. A fused bicyclic heterocycle has a 4 to 7 membered heterocycle fused to a 4 to 7 membered heterocycle or a 3 to 7 membered carbocyclyl. A fused bicyclic heterocyclyl may also have a 4 to 7 membered heterocycle fused to a 5 to 6 membered heteroaryl. Examples include cyclopentapyrrolidinyl, cyclopentapiperidinyl, cyclopentaazapanyl, cyclohexapyrrolidinyl, cyclohexapiperidinyl, cyclohexapazepanyl, cycloheptapyrrolidinyl, cycloheptapiperidinyl, cycloheptapazepanyl, pyrrolopyrrolidinyl, pyrrolopiperidinyl, pyrroloazepanyl, furopyrrolidinyl, furopiperidinyl, furanoazepanyl, pyranopyrrolidinyl, pyranopiperidinyl, pyranoazepanyl, dihydropyrrolo[3,4-d]thiazolyl, and the like.

[0060] A "bridged bicyclic ring system" (also referred to herein as a "bridged bicyclic ring" or "bridged ring system") has 7 to 10 members (ring atoms) and two rings that share three adjacent ring atoms. Bridged bicyclic heterocyclic rings include a 5-7 membered heterocyclic ring that shares three ring atoms with a 5-7 membered heterocyclic ring or a 5-7 membered carbocyclic ring. Examples of nitrogen-containing bridged bicyclic rings include azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[3.3.1]nonyl, diazabicyclo[2.2.1]heptyl, diazabicyclo[3.2.1]octyl, and diazabicyclo[3.3.1]nonyl. Examples of oxygen-containing bridged bicyclic rings include oxobicyclo[2.2.1]heptyl, oxobicyclo[3.2.1]octyl, oxobicyclo[3.3.1]nonyl, oxa-azabicyclo[2.2.1]heptyl, oxa-azabicyclo[3.2.1]octyl and oxa-azabicyclo[3.3.1]nonyl.

[0061] "Spiro ring system" (also referred to herein as "spiro ring") has 8 to 12 members (ring atoms) and two rings sharing one ring atom. Spiro bicyclic heterocycles include 4 to 7 heterocycles that share one atom with 4 to 7 heterocycles or 4 to 7 non-aromatic carbocycles. Examples of 8 to 12 nitrogen-containing spiro ring systems include 3,4-azabicyclooctyl, 4,4-azabicyclononyl, 3,5-azabicyclononyl, 3,6-azabicyclodecyl, 4,5-azabicyclodecyl, 3,7-azabicycloundecyl, 4,6-azabicycloundecyl and 5,5-azabicycloundecyl. Examples of 8-12 oxygen-containing spiro ring systems include 3,4-oxobicyclooctyl, 4,4-oxobicyclononyl, 3,5-oxobicyclononyl, 3,6-oxobicyclodecyl, 4,5-oxobicyclodecyl, 3,7-oxobicycloundecyl, 4,6-oxobicycloundecyl and 5,5-oxobicycloundecyl.

[0062] Examples of 4- to 12-membered nitrogen-containing heterocyclic rings include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, oxepanyl, imidazolinyl, cyclopentapyrrolidinyl, cyclopentapiperidinyl, cyclopentaazepanyl, cyclohexapyrrolidinyl, cyclohexapyrrolidinyl, cyclohexapyrrolidinyl, cyclohexapyrrolidinyl, cyclohexapyrrolidinyl, cycloheptaazepanyl, cycloheptapyrrolidinyl, cycloheptapyrrolidinyl, cycloheptapyrrolidinyl, cycloheptaazepanyl, pyrrolopyrrolidinyl, pyrrolopiperidinyl, pyrroloazepanyl, furopiperidinyl, furanoazepanyl, pyranopyrrolidinyl, pyranopiperidinyl, pyranoazepanyl, azabicyclo[2.2.1]heptyl, azabicyclo[3.2.1]octyl, azabicyclo[3.3.1]nonyl, diazabicyclo[2.2.1]heptyl, diazabicyclo[3.2.1]octyl, diazabicyclo[3.3.1]nonyl, 3,4-azabicyclooctyl, 4,4-azabicyclononyl, 3,5-azabicyclononyl, 3,6-azabicyclodecanyl, 4,5-azabicyclodecanyl, 3,7-azabicycloundecyl, 4,6-azabicycloundecyl and 5,5-azabicycloundecyl. Examples of 4- to 7-membered nitrogen-containing heterocyclic rings (optionally containing one ring oxygen atom or one ring sulfur atom) include pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, azepanyl, oxepanyl and imidazolinyl.

[0063] Examples of the 4- to 7-membered oxygen-containing heterocycle include oxetanyl, tetrahydrofuranyl, oxazolidinyl, isoxazolidinyl, dioxolanyl, oxathiolanyl, tetrahydropyranyl, morpholinyl, dioxanyl, oxepanyl, dihydrofuranyl, and dihydropyranyl.

[0064] The suffix "radical" added to the end of a chemical name indicates that the named moiety is bonded to the molecule at a point. The suffix "sub-unit" added to the end of a chemical name indicates that the named moiety is bonded to the molecule at two points. Examples include azetidinylene, pyrrolindinylene, piperidinylene, azapanylene, or oxazapanylene, which groups indicate that azetidine, pyrrolidine, piperidine, azepane, or oxazaazepanylene is bonded to the rest of the compound at two points.

[0065] A nitrogen-containing heterocycle is "N-substituted" when a ring nitrogen atom is substituted.

[0066] The term "oxo" refers to the diradical =0.

[0067] In the case where the compounds provided herein have sufficient alkalinity or acidity to form stable non-toxic acid or base salts, it may be appropriate to prepare and administer the compounds in the form of pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts are organic acid addition salts formed using acids that form physiologically acceptable anions, such as toluenesulfonates, methanesulfonates, acetates, citrates, malonates, tartrates, succinates, benzoates, ascorbates, alpha-ketoglutarate or alpha-glycerophosphate. Inorganic salts may also be formed, including hydrochlorides, sulfates, nitrates, bicarbonates and carbonates.

[0068] Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid to provide a physiologically acceptable anion. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be prepared.

[0069] Pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts from inorganic bases may include, but are not limited to, sodium salts, potassium salts, lithium salts, ammonium salts, calcium salts or magnesium salts. Salts derived from organic bases may include, but are not limited to, salts of primary, secondary or tertiary amines, such as alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di(substituted alkyl)amines, tri(substituted alkyl)amines, alkenylamines, dienylamines, trialnylamines, substituted alkenylamines, di(substituted alkenyl)amines, tri(substituted alkenyl)amines, cycloalkylamines, di(cycloalkyl)amines, tri(cycloalkyl)amines, substituted cycloalkylamines, disubstituted cycloalkylamines, trisubstituted cycloalkylamines, cycloalkenylamines, di(cycloalkenyl)amines, Tri(cycloalkenyl)amines, substituted cycloalkenylamines, disubstituted cycloalkenylamines, trisubstituted cycloalkenylamines, arylamines, diarylamines, triarylamines, heteroarylamines, diheteroarylamines, triheteroarylamines, heterocycloalkylamines, diheterocycloalkylamines, triheterocycloalkylamines, or mixed diamines and triamines, wherein at least two of the substituents on the amine may be different and may be alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocycloalkyl, etc. Also included are amines wherein two or three substituents together with the amino nitrogen form a heterocycloalkyl or heteroaryl group. Non-limiting examples of amines may include isopropylamine, trimethylamine, diethylamine, tri(isopropyl)amine, tri(n-propyl)amine, ethanolamine, 2-dimethyl-aminoethanol, trimethylamine (trimethamine), lysine, arginine, histidine, caffeine, procaine (procaine), hydrabamine (hydrabamine), choline, betaine, ethylenediamine, glucosamine, N-alkylglucosamine, theobromine, purine, piperazine, piperidine, morpholine or N-ethylpiperidine, etc. Other formic acid derivatives may also be used, such as carboxylic acid amides, including formamide, lower alkyl formamide or dialkyl formamide, etc.

[0070] Compounds as described herein, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers in the molecule. According to the present disclosure, any structure without specifying stereochemistry is understood to encompass all the various stereoisomers (e.g., diastereomers and enantiomers) in pure or substantially pure form, as well as mixtures thereof (such as racemic mixtures or enantiomerically enriched mixtures). How to prepare such optically active forms is well known in the art (for example, resolution of racemic forms by recrystallization techniques, synthesis from optically active starting materials, by chiral synthesis or chromatographic separation using chiral stationary phases).

[0071] When a specific stereoisomer of a compound is shown by name or structure, the stereochemical purity of the compound is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5% or 99.9%. "Stereochemical purity" means the weight percent of the desired stereoisomer relative to the total weight of all stereoisomers.

[0072] When a specific enantiomer of a compound is shown by name or structure, the stereochemical purity of the compound is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5% or 99.9%. "Stereochemical purity" means the weight percent of the desired enantiomer relative to the total weight of all stereoisomers.

[0073] When the stereochemistry of a disclosed compound is named or depicted by structure, and the named or displayed structure encompasses more than one stereoisomer (e.g., as a diastereomeric pair), it is understood that one of the encompassed stereoisomers or any mixture of the encompassed stereoisomers is included. It is also understood that the stereoisomeric purity of the named or displayed stereoisomer is at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 97%, 99%, 99.5%, or 99.9%. The stereoisomeric purity weight % of the desired stereoisomer encompassed by the name or structure is relative to the total weight of all stereoisomers.

[0074] When a disclosed compound is named or shown by structure without indication of stereochemistry, and the compound has one chiral center, it is understood that the name or structure encompasses one enantiomer of the compound in pure or substantially pure form, as well as mixtures thereof (such as racemic mixtures of the compounds and mixtures enriched in one enantiomer relative to the corresponding optical isomer).

[0075] When a disclosed compound is named or shown by structure without indicating stereochemistry and, for example, the compound has at least two chiral centers, it is understood that the name or structure encompasses one stereoisomer in pure or substantially pure form, as well as mixtures thereof (such as stereoisomer mixtures, and stereoisomer mixtures in which one or more stereoisomers are enriched relative to other stereoisomers).

[0076] The disclosed compounds may exist in tautomeric forms and mixtures and encompass the individual tautomers individually. In addition, some compounds may exhibit polymorphism.

[0077] In one embodiment, the present invention provides deuterated compounds disclosed herein, wherein any one or more of the positions occupied by hydrogen may include deuterium enrichment above natural deuterium abundance. For example, one or more hydrogen atoms are replaced with deuterium at an abundance greater than the natural abundance of deuterium by at least 3340 times (the natural abundance of deuterium is 0.015%) (i.e., at least 50.1% deuterium incorporation), at least 3500 times (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 times (60% deuterium incorporation), at least 4500 times (67.5% deuterium incorporation), at least 5000 times (75% deuterium incorporation), at least 5500 times (82.5% deuterium incorporation), at least 6000 times (90% deuterium incorporation), at least 6333.3 times (95% deuterium incorporation), at least 6466.7 times (97% deuterium incorporation), at least 6600 times (99% deuterium incorporation), or at least 6633.3 times (99.5% deuterium incorporation). In one embodiment, hydrogen is present at its natural abundance at all positions. The compounds as described herein, or pharmaceutically acceptable salts thereof, may exist in tautomeric forms and mixtures and the individual tautomers are encompassed individually.

[0078] II. Compounds of the Disclosure

[0079] In a first embodiment, the compounds of the present disclosure are represented by formula (I) or are pharmaceutically acceptable salts thereof, wherein the variables are as described above.

[0080]

[0081] In a second embodiment of the present disclosure, for the compound of formula (I) or a pharmaceutically acceptable salt thereof, R 11 is H; and the remaining variables are as described in the first embodiment.

[0082] In a third embodiment of the present disclosure, the compound is represented by one of the following structural formulas:

[0083]

[0084] or a pharmaceutically acceptable salt thereof; and the remaining variables are as described in the first embodiment.

[0085] In a fourth embodiment of the present disclosure, the compound is represented by one of the following structural formulas:

[0086]

[0087] or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3b are each independently H or halogen, and R 3a and R 3bAt least one of is not H; and the remaining variables are as described in the first embodiment.

[0088] In a fifth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), or a pharmaceutically acceptable salt thereof, R 0 is H, Cl, F or -CH3; and R 3a and R 3b each is F; and the remaining variables are as described in the first, second, third or fourth embodiment.

[0089] In a sixth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), or a pharmaceutically acceptable salt thereof, X 3 Does not exist, -S-, -SO2-, CR 3a R 3b or -(C=O)-NH-*, and R 2 is bonded to X through a ring carbon atom 3 ("C-linked") 4-9 membered monocyclic or bicyclic nitrogen-containing heterocyclic ring, bonded to X via a ring nitrogen atom 3 ("N-linked") 8-9 membered bicyclic nitrogen-containing heterocycle, phenyl or 4-6 membered monocyclic carbocyclic group, wherein R 2 The phenyl group and the 4-6-membered monocyclic carbonyl group represented by R are each represented by 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R 2 The C-linked 4-9-membered monocyclic or bicyclic nitrogen-containing heterocyclic ring represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 and substituted by a group represented by R 2 The N-linked 8-9-membered bicyclic nitrogen-containing heterocycle represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 and the remaining variables are as described in the first, second, fourth or fifth embodiment.

[0090] In a seventh embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), or a pharmaceutically acceptable salt thereof, R 2 is selected from cyclobutyl, cyclopentyl, cyclohexyl and phenyl, each of which is represented by R 4and optionally further substituted with one or two groups represented by R 10 The group represented by 2 is selected from azepanyl, azetidinyl, 9-azabicyclo[3.3.1]nonyl, 2-azabicyclo[2.2.2]octyl, 8-azabicyclo[3.2.1]octyl, 2,7-diazaspiro[4.4]nonane, octahydrocyclopenta[c]pyrrolyl, octahydro-1H-pyrrolo[3,4-c]pyridine, piperidinyl, tetrahydropyridinyl and pyrrolidinyl, each of which is represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented is substituted; and the remaining variables are as described in the sixth embodiment.

[0091] In an eighth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), or a pharmaceutically acceptable salt thereof, R 2 Selected from:

[0092]

[0093] as well as

[0094]

[0095] where m is 0, 1, or 2, and Indicates connection to X 3 or a bond to Ring A; and the remaining variables are as described in the sixth embodiment.

[0096] In a ninth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII) or (IX), or a pharmaceutically acceptable salt thereof, R 2 Selected from:

[0097]

[0098] as well as

[0099]

[0100] in Indicates connection to X 3 or a bond to Ring A; and the remaining variables are as described in the sixth embodiment.

[0101] In a tenth embodiment of the present disclosure, the compound is represented by the following structural formula:

[0102]

[0103] or a pharmaceutically acceptable salt thereof; and the remaining variables are as described in the first embodiment.

[0104] In the eleventh embodiment of the present disclosure, for the compound of formula (X) or a pharmaceutically acceptable salt thereof, R 2 is bonded to X through a ring nitrogen atom 3 ("N-linked") 4-7 membered monocyclic nitrogen-containing heterocyclic ring or 4-6 membered monocyclic carbocyclic ring, wherein R 2 The 4-6 membered monocyclic carbocyclic groups represented by 4 and optionally further substituted with one or two groups represented by R 10 and substituted by a group represented by R 2 The N-linked 4-7-membered monocyclic nitrogen-containing heterocyclic ring represented by R 4 A group represented by R is C-substituted and optionally further substituted with one or two 10 The group represented is substituted; and the remaining variables are as described in the tenth embodiment.

[0105] In the twelfth embodiment of the present disclosure, for the compound of formula (X) or a pharmaceutically acceptable salt thereof, R 2 Selected from:

[0106]

[0107] where m is 0, 1, or 2, and represents a bond to the C(O)-ring A; and the remaining variables are as described in the tenth or eleventh embodiment.

[0108] In the thirteenth embodiment of the present disclosure, for the compound of formula (X) or a pharmaceutically acceptable salt thereof, R 2 Selected from:

[0109]

[0110] in represents a bond to the C(O)-ring A; and the remaining variables are as described in the tenth or eleventh embodiment.

[0111] In the fourteenth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X), or a pharmaceutically acceptable salt thereof, each R 10is independently F, -CH3 or -CH2CH3; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh or twelfth embodiment.

[0112] In the fifteenth embodiment of the present disclosure, for the compound of formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X) or a pharmaceutically acceptable salt thereof,

[0113] R 4 for: R 5 for:

[0114] R 6 is H or -CF3; R 6′ is -CH3; R 7 is H, -CH3 or -CH2CH3; n is 0 or 1, and Indicates connection to R 2 and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth or fourteenth embodiment.

[0115] In the sixteenth embodiment of the present disclosure, for the compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X), or a pharmaceutically acceptable salt thereof, Het is a 5-membered heteroaryl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth or sixteenth embodiment.

[0116] In the seventeenth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X), or a pharmaceutically acceptable salt thereof, Het is pyrazolyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth or fifteenth embodiment.

[0117] In an eighteenth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X), or a pharmaceutically acceptable salt thereof, Het is:

[0118]

[0119] in represents a bond to ring A; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth or fifteenth embodiment.

[0120] In a nineteenth embodiment of the present disclosure, for a compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X), or a pharmaceutically acceptable salt thereof, Het is:

[0121]

[0122] in represents a bond to ring A; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth or fifteenth embodiment.

[0123] In the twentieth embodiment of the present disclosure, for the compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X), or a pharmaceutically acceptable salt thereof, R 1 is C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl; and the remaining variables are as described in the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth or nineteenth embodiment.

[0124] In the twenty-first embodiment of the present disclosure, for the compound of Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX) or (X) or a pharmaceutically acceptable salt thereof, R 1 is -CH3, -CF3, cyclopropyl or cyclobutyl; and the remaining variables are as described in the twentieth embodiment.

[0125] In a twenty-second embodiment of the present disclosure, the compound is represented by one of the following structural formulas:

[0126]

[0127] or a pharmaceutically acceptable salt thereof, wherein: R 0 is H, F or -CH3; R 1 is -CH3, cyclopropyl or cyclobutyl; R 2ais bonded to X through a ring carbon atom 3 ("C-linked") 6-9 membered monocyclic or bicyclic nitrogen-containing heterocyclic ring, the monocyclic or bicyclic nitrogen-containing heterocyclic ring being connected by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by R is substituted; 2b is bonded to X through a ring carbon atom 3 ("C-linked") 4-6 membered monocyclic nitrogen-containing heterocycle, the monocyclic nitrogen-containing heterocycle is connected by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by R is substituted; 2c C 3-6 Cycloalkyl, wherein the cycloalkyl is represented by R 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R is substituted; 2d is bonded to X through a ring carbon atom 3 ("C-linked") 4-7 membered monocyclic nitrogen-containing heterocycle, the monocyclic nitrogen-containing heterocycle is connected by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by the substitution, or C 3-6 Cycloalkyl, wherein the cycloalkyl is represented by R 4 and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted;

[0128] R 4 for: R 5 for: And R 6 It is H or CF3.

[0129] In the twenty-third embodiment of the present disclosure, for the compound of formula (XI), (XII), (XIII) or (XIV) or a pharmaceutically acceptable salt thereof, R 2a is 8-azabicyclo[3.2.1]octyl, octahydrocyclopenta[c]pyrrolyl or piperidinyl, each of which is represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by R is substituted; 2b is azetidinyl or pyrrolidinyl, each of which is represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by R is substituted; 2c is a cyclopentyl group, wherein the cyclopentyl group is represented by R 4and optionally further substituted with one or two groups represented by R 10 is substituted by a group represented by; and R 2d is an azepanyl group, wherein the azepanyl group is represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 A group represented by R is substituted, or a cyclobutyl group, wherein the cyclobutyl group is substituted by R 4 and optionally further substituted with one or two groups represented by R 10 The group represented is substituted; and the remaining variables are as described in the twenty-second embodiment.

[0130] In the twenty-fourth embodiment of the present disclosure, for the compound of formula (XI), (XII), (XIII) or (XIV) or a pharmaceutically acceptable salt thereof,

[0131] R 2a for

[0132] R 2b for R 2c for and

[0133] R 2d for where m is 0, 1, or 2, and Indicates connection to X 3 or a bond to Ring A; and the remaining variables are as described in the twenty-second embodiment.

[0134] In the twenty-fifth embodiment of the present disclosure, for the compound of formula (XI), (XII), (XIII) or (XIV) or a pharmaceutically acceptable salt thereof,

[0135] R 2a for R 2b for

[0137] R 2c for and

[0138] R 2d for

[0139] Where R 10 is -CH3 or -CH2CH3, and Indicates connection to X 3or a bond to Ring A; and the remaining variables are as described in the twenty-second embodiment.

[0140] The present invention also includes both neutral forms and pharmaceutically acceptable salts of the compounds disclosed in the Exemplifications.

[0141] III. Pharmaceutical Compositions and Methods of Use

[0142] Another embodiment is a pharmaceutical composition comprising at least one compound as described herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient and / or carrier.

[0143] The compounds described herein, or pharmaceutically acceptable salts thereof, can be used to reduce the activity of Btk, or otherwise affect the properties and / or behavior of Btk, such as stability, phosphorylation, kinase activity, interaction with other proteins, etc.

[0144] In some embodiments, the present invention provides methods for reducing Btk enzyme activity. In some embodiments, such methods include contacting Btk with an effective amount of a Btk inhibitor. Therefore, the present invention also provides methods for inhibiting Btk enzyme activity by contacting Btk with a Btk inhibitor of the present invention.

[0145] One embodiment of the invention includes a method of treating a condition responsive to Btk inhibition in a subject, the method comprising administering to the subject an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof.

[0146] The term "disorders responsive to Btk inhibition" includes, for example, autoimmune disorders, inflammatory disorders, and cancer. In one embodiment, the present invention provides a method of treating an autoimmune disorder, an inflammatory disorder, and a cancer in a subject in need thereof, comprising administering to the subject an effective amount of at least one compound described herein, or a pharmaceutically acceptable salt thereof.

[0147] The term "autoimmune disorder" includes diseases or disorders involving an inappropriate immune response to a natural antigen, such as acute disseminated encephalomyelitis (ADEM), Addison's disease, alopecia areata, antiphospholipid antibody syndrome (APS), autoimmune hemolytic anemia, autoimmune hepatitis, bullous pemphigoid (BP), celiac disease, dermatomyositis, type 1 diabetes, Goodpasture's syndrome, Graves' disease, Guillain-Barre syndrome, syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, lupus erythematosus, mixed connective tissue disease, multiple sclerosis, myasthenia gravis, pemphigus vulgaris, pernicious anemia, polymyositis, primary biliary cirrhosis, Sjogren's syndrome, temporal arteritis, rheumatoid arthritis, systemic lupus erythematosus, and Wegener's granulomatosis.

[0148] The term "inflammatory disorder" includes diseases or disorders involving acute or chronic inflammation, such as allergies, asthma, prostatitis, glomerulonephritis, pelvic inflammatory disease (PID), inflammatory bowel disease (IBD, e.g., Crohn's disease, ulcerative colitis), reperfusion injury, rheumatoid arthritis, atopic dermatitis, transplant rejection, and vasculitis. In some embodiments, the invention provides a method of treating rheumatoid arthritis or lupus. In some embodiments, the invention provides a method of treating multiple sclerosis.

[0149] The term "cancer" includes diseases or conditions involving abnormal cell growth and / or proliferation, such as glioma, thyroid cancer, breast cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer), gastric cancer, gastrointestinal stromal tumors, pancreatic cancer, bile duct cancer, ovarian cancer, endometrial cancer, prostate cancer, renal cell carcinoma, lymphoma (e.g., anaplastic large cell lymphoma), leukemia (e.g., acute myeloid leukemia, T-cell leukemia, chronic lymphocytic leukemia), multiple myeloma, malignant mesothelioma, malignant melanoma, and colon cancer (e.g., microsatellite-high instability colorectal cancer). In some embodiments, the invention provides a method of treating leukemia or lymphoma.

[0150] As used herein, the terms "subject" and "patient" are used interchangeably and refer to mammals in need of treatment, such as companion animals (e.g., dogs, cats, etc.), farm animals (e.g., cows, pigs, horses, sheep, goats, etc.), and laboratory animals (e.g., rats, mice, guinea pigs, etc.). Typically, the subject is a human in need of treatment.

[0151] As used herein, the term "treating" or "treatment" refers to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic, including partially or substantially achieving one or more of the following results: partially or completely reducing the extent of a disease, disorder, or syndrome; ameliorating or improving clinical symptoms or indications associated with a disorder; or delaying, inhibiting the progression of a disease, disorder, or syndrome or reducing its likelihood.

[0152] An effective dose of a compound provided herein or a pharmaceutically acceptable salt thereof administered to a subject may be 10 μg-500 mg.

[0153] Administration of the compounds described herein or their pharmaceutically acceptable salts to mammals includes any suitable delivery method. Administration of the compounds described herein or their pharmaceutically acceptable salts to mammals includes topical, enteral, parenteral, transdermal, transmucosal, via inhalation, intracisternal, epidural, intravaginal, intravenous, intramuscular, subcutaneous, intradermal or intravitreal administration of the compounds described herein or their pharmaceutically acceptable salts to mammals. Administration of the compounds described herein or their pharmaceutically acceptable salts to mammals also includes topical, enteral, parenteral, transdermal, transmucosal, via inhalation, intracisternal, epidural, intravaginal, intravenous, intramuscular, subcutaneous, intradermal or intravitreal administration of compounds that are metabolized to the compounds described herein or their pharmaceutically acceptable salts in or on the body of mammals.

[0154] Therefore, the compound as described herein or its pharmaceutically acceptable salt can be combined with a pharmaceutically acceptable vehicle (such as an inert diluent or an absorbable edible carrier) for example, orally administered systemically. It can be loaded into a hard shell or soft shell gelatin capsule, it can be compressed into a tablet, or it can be directly combined with the food of the patient's diet. For oral therapeutic administration, the compound as described herein or its pharmaceutically acceptable salt can be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, tablets, capsules, elixirs, suspensions, syrups or compressed tablets. Such compositions and preparations should contain at least about 0.1% of the active compound. Of course, the percentage of the composition and preparation can be varied and can be suitably between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions can be such that an effective dose level will be obtained.

[0155] Tablets, troches, pills, capsules, etc. may include the following substances: binders such as gum tragacanth, gum arabic, corn starch or gelatin; excipients such as dicalcium phosphate; disintegrants such as corn starch, potato starch, alginic acid, etc.; lubricants such as magnesium stearate; or sweeteners such as sucrose, fructose, lactose or aspartame or flavoring agents.

[0156] The active compound may also be administered intravenously or intraperitoneally by infusion or injection.Solutions of the active compound or its salts may be prepared in water, optionally mixed with a nontoxic surfactant.

[0157] Exemplary pharmaceutical dosage forms for injection or infusion may include sterile aqueous solutions or dispersions or sterile powders containing the active ingredient, which are suitable for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions. In all cases, the final dosage form should be sterile, fluid and stable under the conditions of manufacture and storage.

[0158] Sterile injectable solutions can be prepared by combining the required amount of the active compound with various other ingredients listed above (as required) in an appropriate solvent, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred preparation methods may be vacuum drying and freeze drying techniques, which produce a powder of the active ingredient plus any other desired ingredients present in a previously sterile-filtered solution.

[0159] Exemplary solid carriers may include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, etc. Useful liquid carriers include water, ethanol or glycols or water-ethanol / glycol blends, in which the compounds described herein or pharmaceutically acceptable salts thereof may be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.

[0160] The available dosage of a compound as described herein or a pharmaceutically acceptable salt thereof can be determined by comparing its in vitro activity and in vivo activity in an animal model. Methods for extrapolating effective doses in mice and other animals to humans are known in the art; for example, see U.S. Patent No. 4,938,949, which is incorporated herein by reference in its entirety.

[0161] The amount of a compound as described herein or a pharmaceutically acceptable salt thereof required for use in treatment may vary not only with the particular salt selected, but also with the route of administration, the nature of the disorder being treated, and the age and condition of the patient, and may ultimately be determined by the attending physician or clinician. However, in general, dosages may range from about 0.1 to about 10 mg per kilogram of body weight per day.

[0162] The compounds as described herein, or pharmaceutically acceptable salts thereof, may be suitably administered in unit dosage form; for example, each unit dosage form contains 0.01 to 10 mg or 0.05 to 1 mg of active ingredient. In some embodiments, a dose of 5 mg / kg or less may be suitable.

[0163] The desired dose may conveniently be presented in a single dose or in divided doses administered at appropriate intervals.

[0164] The disclosed method may include a kit comprising a compound as described herein or a pharmaceutically acceptable salt thereof and explanatory materials, which may describe administering a compound as described herein or a pharmaceutically acceptable salt thereof or a composition comprising a compound as described herein or a pharmaceutically acceptable salt thereof to a cell or subject. This should be understood to include other embodiments of kits known to those skilled in the art, such as kits comprising a solvent (such as sterile) for dissolving or suspending a compound as described herein or a pharmaceutically acceptable salt thereof or a composition prior to administering a compound as described herein or a pharmaceutically acceptable salt thereof or a composition to a cell or subject. In some embodiments, the subject may be a human.

[0165] The present invention is illustrated by the following examples, which are not intended to be limiting.

[0166] IV.Examples

[0167] A. Abbreviations and acronyms

[0168] Abbreviations and acronyms used in this document include the following:

[0169] ABPR: Automatic Back Pressure Regulator;

[0170] Ac2O: acetic anhydride;

[0171] ACN: acetonitrile;

[0172] Aq.: aqueous solution;

[0173] Ar: argon;

[0174] Bn: benzyl;

[0175] Boc: tert-butoxycarbonyl;

[0176] Boc2O: di-tert-butyl dicarbonate;

[0177] BPin: pinacol boroester;

[0178] (BPin)2 or B2pin2: bis(pinacol)diborane, i.e. 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-di-1,3,2-dioxaborolane;

[0179] br: width;

[0180] t-BuOH: tert-butyl alcohol;

[0181] n-BuLi: n-butyllithium;

[0182] ℃: Celsius;

[0183] CHCl3: chloroform;

[0184] CDCl3: deuterated chloroform;

[0185] CDI: 1,1'-Carbonyldiimidazole

[0186] CO2: Carbon dioxide;

[0187] Cs2CO3: cesium carbonate;

[0188] CsF: cesium fluoride;

[0189] CuI: copper iodide;

[0190] δ: chemical shift;

[0191] d: doublet;

[0192] dd: doublet;

[0193] ddd: doublet of doublets;

[0194] DCM: dichloromethane;

[0195] DIEA or DIPEA: N-ethyldiisopropylamine or N,N-diisopropylethylamine;

[0196] DEA: diethylamine;

[0197] deg: degree;

[0198] Dess-Martin periodinane or DMP: 1,1,1-tri(acetoxy)-1,1-dihydro-1,2-benzoxazol-3-(1H)-one;

[0199] DIAD: diisopropyl azodicarboxylate;

[0200] DABCO: 1,4-diazabicyclo[2.2.2]octane

[0201] DABAL-Me3: adduct of trimethylaluminum and DABCO

[0202] DME: 1,2-dimethoxyethane;

[0203] DMF: N,N-dimethylformamide;

[0204] DMP:

[0205] DMSO: dimethyl sulfoxide;

[0206] DMSO-d6: hexadeuterated dimethyl sulfoxide;

[0207] DPPA: diphenylphosphoryl azide;

[0208] Et: ethyl;

[0209] Et2O: diethyl ether;

[0210] EtOH: ethanol;

[0211] EA or EtOAc: ethyl acetate;

[0212] Eq.: equivalent;

[0213] g: grams;

[0214] h: hour;

[0215] HATU: O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate;

[0216] HE: heptane;

[0217] HBr: hydrogen bromide;

[0218] HCl: hydrochloric acid;

[0219] HCO2H: formic acid;

[0220] Hept: heptane;

[0221] HFIP: hexafluoroisopropanol;

[0222] 1 H NMR: proton nuclear magnetic resonance;

[0223] H2O: water;

[0224] H2SO4: sulfuric acid;

[0225] HMPA: hexamethylphosphoramide;

[0226] HPLC: high pressure liquid chromatography;

[0227] Hz: Hertz;

[0228] IPA or iPrOH: isopropyl alcohol;

[0229] J: coupling constant;

[0230] K2CO3: potassium carbonate;

[0231] kg: kilogram;

[0232] KHMDS: potassium hexamethyldisilazane;

[0233] KOAc: potassium acetate;

[0234] KOH: potassium hydroxide;

[0235] KOt-Bu: Potassium tert-butoxide

[0236] K3PO4: tripotassium phosphate;

[0237] K4Fe(CN)6·3H2O: potassium hexacyanoferrate (II) trihydrate;

[0238] L: liter;

[0239] LCMS: liquid chromatography mass spectrometry;

[0240] LG: leaving group;

[0241] m: multiple peak;

[0242] M: molar;

[0243] MBPR: Manual Back Pressure Regulator;

[0244] Me: methyl;

[0245] MeB(OH)2: methylboronic acid;

[0246] MeCN: acetonitrile;

[0247] MeOH: methanol;

[0248] MeOH-d4: deuterated methanol;

[0249] mg: milligram;

[0250] MgSO4: magnesium sulfate;

[0251] MHz: megahertz;

[0252] min: minute;

[0253] mL: milliliter;

[0254] mmol: millimole;

[0255] MMPNO: methylmorpholine N-oxide;

[0256] mol: mole;

[0257] MS m / z: mass spectrum peak;

[0258] N2: Nitrogen;

[0259] NaOt-Bu: sodium tert-butoxide;

[0260] NaH: sodium hydride;

[0261] NaHCO3: sodium bicarbonate;

[0262] NaHMDS: sodium hexamethyldisilazane;

[0263] NaOH: sodium hydroxide;

[0264] Na2S2O3: sodium thiosulfate;

[0265] Na2SO4: sodium sulfate;

[0266] NEt3: triethylamine;

[0267] NFSI: N-fluorobenzenesulfonimide;

[0268] NH3: ammonia water;

[0269] NH4Cl: ammonium chloride;

[0270] NH4OH: ammonium hydroxide;

[0271] NH4OAc: ammonium acetate;

[0272] NIS: N-iodosuccinimide;

[0273] OsO4: osmium tetroxide;

[0274] P(cy)3: tricyclohexylphosphine;

[0275] Pd2(dba)3: tris(dibenzylideneacetone)dipalladium(0);

[0276] Pd(dppf)Cl2: [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II);

[0277] Pd(dppf)Cl2·DCM: [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) complex with dichloromethane

[0278] Pd(dtbpf)Cl2: [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II);

[0279] Pd(t-Bu3P)2: bis(tri-tert-butylphosphine)palladium(0);

[0280] PE: Petroleum ether

[0281] PEPPSI-IPr or Pd-PEPPSI-IPr: [1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)palladium(II) dichloride

[0282] PG: protecting group;

[0283] Ph: phenyl;

[0284] POCl3: phosphorus oxychloride;

[0285] Pyr: pyridine;

[0286] q: quartet;

[0287] Rf: Retardation coefficient;

[0288] Rt: residence time;

[0289] rt or RT: room temperature;

[0290] Rh(OAc)2 dimer: rhodium(II) acetate dimer;

[0291] RuPhos: 2-dicyclohexylphosphino-2′,6′-diisopropoxybiphenyl;

[0292] s: single peak;

[0293] sat.: saturated;

[0294] SCX: strong cation exchange;

[0295] SFC: supercritical fluid chromatography;

[0296] SiO2: Silicon dioxide;

[0297] Si-SPE: silica solid phase extraction;

[0298] SPE: solid phase extraction;

[0299] t: triplet;

[0300] td: triplet;

[0301] t-BuONa: sodium tert-butoxide;

[0302] TEA: triethylamine;

[0303] TFA: trifluoroacetic acid;

[0304] Tf2O: trifluoromethanesulfonic anhydride;

[0305] THF: tetrahydrofuran;

[0306] TLC: thin layer chromatography;

[0307] TsNHNH2: p-toluenesulfonyl hydrazide;

[0308] T3P: propanephosphonic anhydride;

[0309] μL: microliter;

[0310] μmol: micromole;

[0311] μW: microwave;

[0312] v / v: volume / volume;

[0313] Xphos: 2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl;

[0314] Xphos G3: (2-dicyclohexylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)[2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate;

[0315] tBuXPhos Pd G3: [(2-di-tert-butylphosphino-2′,4′,6′-triisopropyl-1,1′-biphenyl)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate

[0316] B. experiment

[0317] Example 1 :1-[(3aS,6aR)-5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one

[0318]

[0319] Preparation of tert-butyl 1.5-(trifluoromethylsulfonyloxy)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate

[0320]

[0321] A solution of tert-butyl 5-oxo-1,3,3a,4,6,6a-hexahydrocyclopenta[c]pyrrole-2-carboxylate (1.61 g, 7.15 mmol) in THF (20 mL) was cooled to -78 °C and potassium [bis(trimethylsilyl)amide] (1 M, 7.58 mL) was added dropwise. After stirring at 0 °C for 2 h, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonic acid amide (3.83 g, 10.72 mmol) was added in one go. The mixture was allowed to warm to room temperature overnight. NH4Cl aqueous solution (saturated) was added and extracted with EA. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (EA / Hept.; 0-100%) to give tert-butyl 5-(trifluoromethylsulfonyloxy)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (2.2 g, 6.16 mmol, 86% yield) as a colorless oil. LCMS (ESI+): C 13 H 19 m / z calculated for F3NO5S [M+H]+, 358.1; found, 358.1. Rt = 0.98 min. 1 H NMR (400MHz, CDCl3, δ): 5.58 (d, J=1.5Hz, 1H), 3.63-3.80 (m, 1H), 3.47-3.59 (m, 1H), 3.40 (qd, J=5.2, 2.4Hz, 2H), 3.16 (br s,1H),2.85-3.00(m,2H),2.40(br d,J=14.8Hz,1H),1.41-1.48(m,9H).

[0322] Preparation of tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate

[0323]

[0324] To a solution of tert-butyl 5-(trifluoromethylsulfonyloxy)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (606 mg, 1.70 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (861.28 mg, 3.39 mmol) in dioxane was added Pd(dppf)Cl2.DCM (138.49 mg, 169.58 umol) and KOAc (499.29 mg, 5.09 mmol). The mixture was stirred at 90° C. under N2 for 12 h. After filtration through celite, the reaction mixture was concentrated under vacuum to give a crude material, which was purified by silica gel column chromatography (PE / EA=7 / 3) to give tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (386 mg, 1.15 mmol, 68% yield) as a colorless oil. LCMS (ESI+): C 13 H 23 m / z calculated for BNO2 [M+H-C5H8O2] + , 236.2; experimental value, 236.3. Rt=1.02min. 1 H NMR (400MHz, CDCl3, δ): 6.33 (s, 1H), 3.57-3.67 (m, 1H), 3.47-3.54 (m, 1H), 3.41-3.46 (m, 1H), 3.34-3.40 (m, 1H), 2 .93-2.98(m,1H),2.83-2.92(m,1H),2.57-2.70(m,1H),2.28-2.44(m,1H),1.42-1.46(m,9H),1.27-1.28(m,12H).

[0325] 3. Preparation of tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate

[0326]

[0327] Water (1 mL) containing 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (200 mg, 855.96 umol), tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (401.74 mg, 1.20 mmol), K2CO3 (354.91 mg, 2.57 mmol), tetrakis(triphenylphosphine)palladium(0) (197.82 mg, 171.19 umol) and dioxane (6 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (DCM / EtOAc 0-100%) to give tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (309 mg, 760.19 umol, 89% yield) as a white solid. LCMS (ESI+): C 22 H 27 m / z calculated for N6O2 [M+H] + , 407.2; experimental value, 407.3. Rt=0.82min. 1 HNMR (400MHz, CDCl3, δ): 8.42-8.47 (m, 1H), 7.97-8.15 (m, 1H), 7.91 (d, J = 7.4Hz, 2H), 6.90 (d, J = 2.0Hz, 1 H),6.67(s,1H),3.99(s,3H),3.53-3.78(m,4H),3.14-3.31(m,2H),3.01-3.14(m,2H),1.42-1.50(m,9H).

[0328] 4. Preparation of 4-(1,2,3,3a,6,6a-hexahydrocyclopenta[c]pyrrol-5-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine

[0329]

[0330] To tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (309 mg, 760.19 umol) in DCM (4 mL) was added TFA (86.68 mg, 760.19 umol, 58.21 uL) and stirred at room temperature for 1 h. LCMS (ESI+): C17 H 19 m / z calculated for N6 [M+H] + , 307.2; Found, 307.1. Rt = 0.44 min. The crude material was concentrated and used as is in the next step.

[0331] 5. Preparation of 4-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine

[0332]

[0333] To 4-(1,2,3,3a,6,6a-hexahydrocyclopenta[c]pyrrol-5-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (0.78 g, 1.71 mmol, trifluoromethanesulfonic acid) in MeOH (10 mL) was added Pd(OH)2 / C (120.00 mg, 170.89 umol, 20% purity) and stirred under H2 at 60 psi at room temperature for 2 days. After filtration through celite, the concentrated residue 4-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (392 mg, 928.02 umol, 54% yield, TFA salt) was used as is in the next step. LCMS (ESI+): C 17 H 21 m / z calculated for N6 [M+H] + , 309.2; experimental value, 309.2. Rt = 0.44min.

[0334] 6. Preparation of 1-[(3aS,6aR)-5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one

[0335]

[0336] To 4-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (392 mg, 928.02 umol, TFA) in DCM (5 mL) was added TEA (187.81 mg, 1.86 mmol, 258.70 uL) and stirred for 5 min. After cooling to 0 °C, acryloyl chloride (100.79 mg, 1.11 mmol, 90.48 uL) was added and stirred for 3 min. The reaction was quenched with saturated aqueous NaHCO3 and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) to give 1-[(3aS,6aR)-5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one (62.2 mg, 166.47 umol, 18% yield, 97% purity) as Peak 2. LCMS (ESI+): C 20 H 23 m / z calculated for N6O [M+H] + , 363.2; experimental value, 363.2. Rt = 0.63min. 1 H NMR (400MHz, CDCl3, δ): 8.42 (s, 1H), 7.95 (d, J = 2.51Hz, 1H), 7.92 (s, 1H), 7.87 (s, 1H), 6.72 (dd, J = 0.88, 2.38Hz, 1H), 6.51-6.37 (m, 2H), 5.6 9(dd,1H,J=2.5,10.0Hz),3.99(s,3H),3.85-3.76(m,4H),3.64(dd,1H,J=4.4,10.7Hz),3.01-2.84(m,2H),2.47(brt,1H,J=7.9Hz),2.43(br t,1H,J=7.8Hz),2.17-2.01(m,2H).

[0337] Example 2 :1-[(3aS,6aR)-5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one

[0338]

[0339] 1-[(3aS,6aR)-5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one (20 mg, 52.42 umol, 6% yield, 95% purity) was isolated as Peak 1 as a white solid using Example 1. LCMS (ESI+): C 20 H 23 m / z calculated for N6O [M+H] + , 363.2; experimental value, 363.2. Rt = 0.61min. 1 H NMR(400MHz,CDCl3,δ):8.41(s,1H),7.94(brs,1H),7.89(s,1H),7.87(s,1H),6.70(brs,1H),6.52-6.37(m,2H ),5.71-5.68(m,1H),3.97(s,3H),3.87-3.48(m,5H),3.07-2.98(m,2H),2.53-2.41(m,2H),2.07-1.99(m,2H).

[0340] Example 3 .1-[5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one

[0341]

[0342] 1. Preparation of tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate

[0343]

[0344] [6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]trifluoromethanesulfonate (300 mg, 866.34 umol), tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (435.65 mg, 1.30 mmol), K2CO3 (359.21 mg, 2.60 mmol), tetrakis(triphenylphosphine)palladium(0) (100.11 mg, 86.63 umol) in water (1 mL) and dioxane (6 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (DCM / EtOAc 0-100%) to give tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (290 mg, 715.18 umol, 83% yield) as a white solid. LCMS (ESI+): C 23 H 28 m / z calculated for N5O2 [M+H] + , 406.2; experimental value, 406.2. Rt=0.85min.

[0345] 2. Preparation of 4-(1,2,3,3a,6,6a-hexahydrocyclopenta[c]pyrrol-5-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine

[0346]

[0347] To tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,3a,6,6a-tetrahydro-1H-cyclopenta[c]pyrrole-2-carboxylate (290 mg, 715.18 umol) in DCM (4 mL) was added TFA (744.50 mg, 6.53 mmol, 0.5 mL) and stirred at room temperature for 1 h. LCMS (ESI+): C 18 H 20 m / z calculated for N5 [M+H] + , 306.2; Found, 306.2. Rt = 0.52 min. The crude material was concentrated and used as is in the next step.

[0348] 3. Preparation of 4-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine

[0349]

[0350] To 4-(1,2,3,3a,6,6a-hexahydrocyclopenta[c]pyrrol-5-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine (790 mg, 1.88 mmol, TFA) in MeOH (10 mL) was added Pd(OH)2 / C (132.27 mg, 188.36 umol, 20% purity) and stirred under H2 at 60 psi at room temperature for 2 days. After filtration through celite, the concentrated residue 4-[(3aS,6aR)-1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrol-5-yl]-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine (0.35 g, 765.08 umol, 41% yield, TFA) was used as such in the next step. LCMS (ESI+): C 18 H 22 m / z calculated for N5 [M+H] + , 308.2; experimental value, 308.1. Rt = 0.51min.

[0351] 4. Preparation of 1-[5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one

[0352]

[0353] To DCM (5 mL) containing 4-(1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole-5-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridine (350 mg, 830.54 umol, TFA) was added TEA (168.08 mg, 1.66 mmol, 231.52 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (90.21 mg, 996.64 umol, 80.97 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-50%) to give 1-[5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrol-2-yl]prop-2-en-1-one (89 mg, 233.93 umol, 28% yield, 95% purity). LCMS (ESI+): C 21 H 24 m / z calculated for N5O [M+H] + , 362.2; experimental value, 362.2. Rt = 0.62min. 1 H NMR (400MHz, CDCl3, δ):8.82(br s,1H),7.99(br s,1H),7.71-7.84(m,2H),7.20-7.25(m,1H),6.60(br s,1H),6.38-6.53(m,2H),5.70-5.74(m,1H),3.96-4.03(m,3H),3.75(br d,J=6.0Hz,3H),3.61(br s,1H),3.39-3.56(m,1H),2.95(br s,2H),2.42-2.63(m,2H),2.34(br s,2H).

[0354] Example 4 .1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0355]

[0356] 1. Preparation of tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate

[0357]

[0358] 4-Chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (214 mg, 915.87 umol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (424.79 mg, 1.37 mmol), KCO (379.75 mg, 2.75 mmol), tetrakis(triphenylphosphine)palladium(0) (211.67 mg, 183.17 umol) in 1,2-dimethoxyethane (5 mL) and water (1 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (DCM / EtOAc 0-100%) to give tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (144 mg, 378.51 umol, 41% yield) as a white solid. LCMS (ESI+): C 20 H 25 m / z calculated for N6O2 [M+H] + , 381.2; experimental value, 381.2. Rt=0.83min.

[0359] 2. Preparation of tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidine-1-carboxylate

[0360]

[0361] To a flask containing Pd(OH)2 / C (53.16 mg, 75.70 umol, 20% purity) was added a solution of tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (144 mg, 378.51 umol) in MeOH (5 mL). The mixture was stirred under 50 bar H2 for 16 h. LCMS: Rt = 0.88 min, m / z 384.2. After filtration through celite, the concentrated residue tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidine-1-carboxylate (143 mg, 373.90 umol, 99% yield) was used as is. LCMS (ESI+): C 20 H 27 m / z calculated for N6O2 [M+H] + , 383.2; experimental value, 383.2. Rt = 0.83min.

[0362] 3. Preparation of 6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyrazine

[0363]

[0364] To tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]piperidine-1-carboxylate (143 mg, 373.90 umol) in DCM was added TFA (42.63 mg, 373.90 umol, 28.63 uL) and stirred for 1 h. After concentration, the crude residue was used as is in the next step. LCMS (ESI+): C 15 H 19 m / z calculated for N6 [M+H] + , 283.2; experimental value, 283.1. Rt = 0.47min.

[0365] 4. Preparation of 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0366]

[0367] To DCM (4 mL) containing 6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyrazine (269 mg, 678.67 umol, TFA salt) was added TEA (137.35 mg, 1.36 mmol, 189.19 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (73.71 mg, 814.40 umol, 66.17 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) and preparative HPLC to give 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one (38.7 mg, 109.29 umol, 16% yield, 95% purity) as a white solid. LCMS (ESI+): C 18 H 21 m / z calculated for N6O [M+H] + , 337.2; experimental value, 337.1. Rt = 0.58min. 1H NMR (400MHz, CDCl3, δ):8.45-8.47(m,1H),7.99-8.01(m,1H),7.96-7.99(m ,1H),7.89-7.91(m,1H),6.78-6.81(m,1H),6.62-6.70(m,1H),6.30-6.38(m ,1H),5.71-5.76(m,1H),4.79-4.92(m,1H),4.17-4.26(m,1H),4.00(s,3H), 3.42-3.53(m,1H),3.29-3.40(m,1H),2.93-3.02(m,1H),2.06-2.11(m,4H).

[0368] Example 5 .1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0369]

[0370] 1. Preparation of 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl ester

[0371]

[0372] Water (1 mL) containing 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (238 mg, 1.02 mmol), 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl ester (524.41 mg, 1.53 mmol), KCO (422.34 mg, 3.06 mmol), tetrakis(triphenylphosphine)palladium(0) (235.41 mg, 203.72 umol) and dioxane (5 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (DCM / EtOAc 0-100%) to give 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl ester (363 mg, 875.84 umol, 85.99% yield) as a white solid. LCMS (ESI+): C 23 H 23 m / z calculated for N6O2 [M+H] +, 415.2; experimental value, 415.1. Rt=0.84min.

[0373] 2. Preparation of 6-(1-methylpyrazol-4-yl)-4-(3-piperidinyl)pyrazolo[1,5-a]pyrazine

[0374]

[0375] Pd(OH)2 / C (123.00 mg, 875.84 umol) was added to 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,4-dihydro-2H-pyridine-1-carboxylic acid benzyl ester (363 mg, 875.84 umol) in THF (10 mL) and stirred under H2 for 2 days. After filtration through celite, the concentrated residue was used as is in the next step. LCMS (ESI+): C 15 H 19 m / z calculated for N6 [M+H] + , 283.2; experimental value, 283.0. Rt = 0.49min.

[0376] 3. Preparation of 1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0377]

[0378] To DCM (4 mL) containing 6-(1-methylpyrazol-4-yl)-4-(3-piperidinyl)pyrazolo[1,5-a]pyrazine (126 mg, 446.27 umol) was added TEA (90.32 mg, 892.53 umol, 124.40 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (48.47 mg, 535.52 umol, 43.51 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) to give 1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one (18.3 mg, 53.31 umol, 12% yield, 98% purity) as a white solid. LCMS (ESI+): C 18 H 21 m / z calculated for N6O [M+H] + , 337.2; experimental value, 337.1. Rt = 0.58min. 1H NMR(400MHz, CDCl3,d):8.49-8.43(m,1H),8.01-7.89(m,3H),6.95-6.79(m,1H),6.72-6.59(m,1H),6.39-6.27(m,1H),5.79-5.66(m,1H),5.0 3-4.83(m,1H),4.74-4.58(m,1H),4.03(s,3H),3.38-3.17(m,2H),2.34 -2.20(m,2H),2.16-2.06(m,1H),2.00-1.93(m,1H),1.80-1.68(m,1H).

[0379] Example 6 .1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]azepan-1-yl]prop-2-en-1-one

[0380]

[0381] 1. Preparation of tert-butyl 4-oxoazepane-1-carboxylate

[0382]

[0383] To tert-butyl 4-hydroxyazepane-1-carboxylate (300 mg, 1.39 mmol) in DCM (10 mL) was added Dess-Martin periodinane (886.55 mg, 2.09 mmol) and stirred at room temperature for 16 h. After filtration through celite, the concentrated residue was purified by silica gel column chromatography (HE / EA 0-100%) to give tert-butyl 4-oxoazepane-1-carboxylate (297 mg, 1.39 mmol, 99.94% yield) as an oil. 1 H NMR (400MHz, CDCl3,d): 3.50-3.66(m,4H), 2.55-2.73(m,4H), 1.73-1.86(m,2H), 1.46(s,9H).

[0384] Preparation of tert-butyl 2.5-(trifluoromethylsulfonyloxy)-2,3,4,7-tetrahydroazepine-1-carboxylate

[0385]

[0386] Tert-butyl 4-oxoazepane-1-carboxylate (297 mg, 1.39 mmol) was cooled to -78 °C and potassium [bis(trimethylsilyl)amide] (1 M, 1.48 mL) was added dropwise. After stirring at 0 °C for 2 h, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonic acid amide (746.25 mg, 2.09 mmol) was added in one go. The mixture was allowed to warm to room temperature overnight. NH4Cl (saturated) was added and extracted with EA. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (EA / Hept. (0-100%) to give tert-butyl 5-(trifluoromethylsulfonyloxy)-2,3,4,7-tetrahydroazepine-1-carboxylate (404 mg, 1.17 mmol, 84% yield) as a colorless oil.

[0387] Preparation of tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,7-tetrahydroazepine-1-carboxylate

[0388]

[0389] To a solution of tert-butyl 5-(trifluoromethylsulfonyloxy)-2,3,4,7-tetrahydroazepine-1-carboxylate (404 mg, 1.17 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (594.15 mg, 2.34 mmol) in dioxane (5 mL) was added KOAc (344.44 mg, 3.51 mmol) and Pd(dppf)Cl2DCM (95.54 mg, 116.99 umol). The mixture was stirred at 90 °C under N2 for 12 h. After filtration through celite, the reaction mixture was concentrated under vacuum to give the crude material, which was purified by silica gel column chromatography (PE / EA=7 / 3) to give tert-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3,4,7-tetrahydroazepine-1-carboxylate (550 mg) as a white solid.

[0390] 4. Preparation of tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2,3,4,7-tetrahydroazepine-1-carboxylate

[0391]

[0392] Water (1 mL) containing 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (263.45 mg, 1.13 mmol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)cyclohept-3-ene-1-carboxylate (545 mg, 1.69 mmol), KCO (467.50 mg, 3.38 mmol), tetrakis(triphenylphosphine)palladium(0) (260.58 mg, 225.50 umol) and dioxane (5 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (DCM / EtOAc 0-100%) to give tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2,3,4,7-tetrahydroazepine-1-carboxylate (404 mg, 1.02 mmol, 91% yield) as an oil. LCMS (ESI+): C 21 H 27 m / z calculated for N6O2 [M+H] + , 395.2; experimental value, 395.2. Rt = 0.83min.

[0393] 5. Preparation of tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]azepane-1-carboxylate

[0394]

[0395] To a flask containing Pd(OH)2 / C (71.92 mg, 102.42 umol, 20% purity) was added a solution of tert-butyl 5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2,3,4,7-tetrahydroazepine-1-carboxylate (404 mg, 1.02 mmol) in THF (5 mL). The mixture was stirred at 50 bar H2 for 16 h. After filtration through celite, the concentrated residue, tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]azepane-1-carboxylate (315 mg, 794.48 umol, 78% yield), was used as is. LCMS (ESI+): C 21 H 29 m / z calculated for N6O2 [M+H] + , 397.2; experimental value, 397.3. Rt = 0.86min.

[0396] 6. Preparation of 4-(azepan-4-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine

[0397]

[0398] To tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-yl]azepane-1-carboxylate (315 mg, 794.48 umol) in DCM (3 mL) was added TFA (744.50 mg, 6.53 mmol, 0.5 mL) and stirred for 16 h. After concentration, the crude residue 4-(azepan-4-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (342 mg, TFA salt) was used as is in the next step. LCMS (ESI+): C 16 H 21 m / z calculated for N6 [M+H] + , 297.2; experimental value, 297.1. Rt = 0.48min.

[0399] 7. Preparation of 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]azepan-1-yl]prop-2-en-1-one

[0400]

[0401] To DCM (4 mL) containing 4-(azepan-4-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (342 mg, 833.35 umol, TFA salt) was added TEA (168.65 mg, 1.67 mmol, 232.30 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (90.51 mg, 1.00 mmol, 81.25 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) and preparative HPLC to give 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]azepan-1-yl]prop-2-en-1-one (17.2 mg, 46.63 umol, 5.6% yield, 95% purity) as a white solid. LCMS (ESI+): C 19 H 23 m / z calculated for N6O [M+H] + , 351.1; experimental value, 351.1. Rt=0.58min. 1H NMR(400MHz CDCl3,d):8.47-8.54(m,1H),8.26-8.34(m,1H),8.04(s,1H),7.88-7.92(m,1H),6.79-6.92(m,1H),6.62-6 .70(m,1H),6.41-6.47(m,1H),5.72-5.78(m,1H),3.99-4.03(m,3H),3.63-3.86(m,4H),1.82-2.33(m,7H).

[0402] Example 7 .1-[4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0403]

[0404] 1. Preparation of tert-butyl 4-(6-chloro-3-fluoro-pyrazolo[1,5-a]pyrazine-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylate

[0405]

[0406] Water (0.3 mL) and dioxane (2 mL) containing 4,6-dichloro-3-fluoro-pyrazolo[1,5-a]pyrazine (200 mg, 970.85 umol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (300.20 mg, 970.85 umol), KCO (402.54 mg, 2.91 mmol), tetrakis(triphenylphosphine)palladium(0) (112.19 mg, 97.09 umol) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (DCM / EtOAc 0-100%) to give tert-butyl 4-(6-chloro-3-fluoro-pyrazolo[1,5-a]pyrazin-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (246 mg, 697.30 umol, 72% yield) as a white solid. LCMS (ESI+): C 11 H 11 m / z calculated for ClFN4 [M+H-Boc] + , 253.1; experimental value, 253.0. Rt = 0.96min.

[0407] 2. Preparation of tert-butyl 4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate

[0408]

[0409] 4-(6-chloro-3-fluoro-pyrazolo[1,5-a]pyrazin-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (246 mg, 697.30 umol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (217.62 mg, 1.05 mmol), Pd(dppf)Cl2CH2Cl2 (56.94 mg, 69.73 umol), K2CO3 (289.12 mg, 2.09 mmol) in dioxane (2 mL) and water (0.3 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was filtered through celite and concentrated. The residue was purified by silica gel column chromatography (HE / EA 0-100%) to give tert-butyl 4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (236 mg, 592.32 umol, 85% yield) as a light yellow gel. LCMS (ESI+): C 20 H 24 m / z calculated for FN6O2 [M+H] + , 399.2; experimental value, 399.2. Rt = 0.86min.

[0410] 3. Preparation of 3-fluoro-6-(1-methylpyrazol-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyrazine

[0411]

[0412] To tert-butyl 4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (236 mg, 592.32 umol) in DCM (3 mL) was added TFA (744.50 mg, 6.53 mmol, 0.5 mL) and stirred for 16 h. After concentration, the crude residue was used as is in the next step. LCMS (ESI+): C 15 H 16 m / z calculated for FN6 [M+H] + , 299.2; experimental value, 299.0. Rt = 0.53min.

[0413] 4. Preparation of 3-fluoro-6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyrazine

[0414]

[0415] To a flask containing Pd(OH)2 / C (187.33 mg, 266.77 umol, 20% purity) was added a solution of 3-fluoro-6-(1-methylpyrazol-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyrazine (550 mg, 1.33 mmol, TFA) in MeOH (5 mL). The mixture was stirred under H2 for 16 h. After filtration and concentration, the crude material was used as is in the next step. LCMS (ESI+): C 15 H 18 m / z calculated for FN6 [M+H] + , 301.2; experimental value, 301.1. Rt = 0.48min.

[0416] 5. Preparation of 1-[4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0417]

[0418] To DCM (5 mL) containing 3-fluoro-6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyrazine (233 mg, 775.80 umol, TFA salt) was added TEA (157.01 mg, 1.55 mmol, 216.26 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (84.26 mg, 930.97 umol, 75.64 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) and preparative HPLC to give 1-[4-[3-fluoro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one (36 mg, 96.51 umol, 12% yield, 95% purity) as a white solid. LCMS (ESI+): C 18 FH 20 m / z calculated for N6O [M+H] + , 355.2; experimental value, 355.1. Rt = 0.63min. 1H NMR(400MHz, CDCl3,d):8.09-8.36(m,2H),7.91-8.02(m,1H),7.79-7.88(m,1H),6.60-6.74(m,1H),6.29-6 .41(m,1H),5.69-5.79(m,1H),3.88-4.14(m,3H),3.48-3.62(m,1H),3.02-3.29(m,2H),1.87-2.16(m,6H). 19 F NMR (376MHz, CDCl3,d): -171.56 (s, 1F).

[0419] Example 8 .1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0420]

[0421] 1. Preparation of trifluoromethanesulfonic acid [6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl] ester

[0422]

[0423] Pyridine (147.70 mg, 1.87 mmol, 151.02 uL) and trifluoromethanesulfonic anhydride (316.09 mg, 1.12 mmol, 188.48 uL) were added to DCM (4 mL) containing 6- (1-methylpyrazol-4-yl) pyrazolo [1,5-a] pyridine-4-ol (200 mg, 933.61 umol) and stirred at room temperature for 16 h. After concentration, the residue was purified by silica gel column chromatography (EA / HE 0-100%) to give trifluoromethanesulfonic acid [6- (1-methylpyrazol-4-yl) pyrazolo [1,5-a] pyridine-4-yl] ester (219 mg, 632.43 umol, 68% yield) as a white solid. LCMS (ESI+): C 12 H 10 m / z calculated for F3N4O3S [M+H] + , 347.0; experimental value, 347.0. Rt = 0.79min.

[0424] 2. Preparation of tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate

[0425]

[0426] The water (0.3 mL) containing [6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]trifluoromethanesulfonate (219 mg, 632.43 umol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (195.55 mg, 632.43 umol), KCO (262.22 mg, 1.90 mmol), tetrakis(triphenylphosphine)palladium(0) (73.08 mg, 63.24 umol) and dioxane (2 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (EtOAc / DCM 0-100%) to give tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (235 mg, 619.31 umol, 98% yield) as a gel. LCMS (ESI+): C 21 H 26 m / z calculated for N5O2 [M+H] + , 380.2; experimental value, 380.2. Rt=0.82min.

[0427] 3. Preparation of 6-(1-methylpyrazol-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyridine

[0428]

[0429] To tert-butyl 4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (235 mg, 619.31 umol) in DCM (3 mL) was added TFA (744.50 mg, 6.53 mmol, 0.5 mL) and stirred at room temperature for 1 h. The crude material was concentrated and used as is in the next step. LCMS (ESI+): C 16 H 18 m / z calculated for N5 [M+H] + , 280.2; experimental value, 280.0. Rt=0.50min.

[0430] 4. Preparation of 6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyridine

[0431]

[0432] Pd(OH)2 / C (165.16 mg, 235.20 umol, 20% purity) was added to 6-(1-methylpyrazol-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyridine (657 mg, 2.35 mmol) in MeOH (6 mL) and stirred at room temperature for 16 h under H2. After filtration through celite, the concentrated residue was used as is in the next step. LCMS (ESI+): C 16 H 20 m / z calculated for N5 [M+H] + , 282.2; experimental value, 282.1. Rt = 0.48min.

[0433] 5. Preparation of 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0434]

[0435] To DCM (5 mL) containing 6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyridine (249 mg, 629.78 umol, TFA salt) was added TEA (127.45 mg, 1.26 mmol, 175.56 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (68.40 mg, 755.73 umol, 61.40 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) and preparative HPLC to give 1-[4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyridin-4-yl]-1-piperidinyl]prop-2-en-1-one (82 mg, 244.48 umol, 39% yield) as a white solid. LCMS (ESI+): C 19 H 22 m / z calculated for N5O [M+H] + , 336.2; experimental value, 336.1. Rt = 0.57min. 1H NMR (400MHz, CDCl3, d): 8.56 (s, 1H), 7.95 (d, J = 2.3Hz, 1H), 7.75 (d, J = 0.8Hz, 1H ),7.55-7.69(m,1H),7.05(s,1H),6.59-6.74(m,1H),6.56(dd,J=0.9,2.38Hz,1H ),6.34(dd,J=2.0,16.82Hz,1H),5.74(dd,J=1.8,10.5Hz,1H),4.86-5.03(m,1H ),4.13-4.31(m,1H),3.98(s,3H),3.22-3.37(m,1H),2.97-3.22(m,1H),2.82(br s,1H),2.07-2.16(m,2H),1.80(br s,2H).

[0436] Example 9 .1-[4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0437]

[0438] 1. Preparation of tert-butyl 4-(6-chloro-3-methyl-pyrazolo[1,5-a]pyrazine-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylate

[0439]

[0440] Water (0.3 mL) and dioxane (2 mL) containing 4,6-dichloro-3-methyl-pyrazolo[1,5-a]pyrazine (200 mg, 989.90 umol), tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (306.09 mg, 989.90 umol), KCO (410.44 mg, 2.97 mmol), tetrakis(triphenylphosphine)palladium(0) (114.39 mg, 98.99 umol) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (EtOAc / DCM 0-100%) to give tert-butyl 4-(6-chloro-3-methyl-pyrazolo[1,5-a]pyrazin-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylate (281 mg, 805.56 umol, 82% yield) as a gel. LCMS (ESI+): C 17 H 22m / z calculated for ClN4O2 [M+H] + , 349.1; experimental value, 349.0. Rt = 0.94min.

[0441] 2. Preparation of tert-butyl 4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate

[0442]

[0443] The dioxane (2 mL) containing 4-(6-chloro-3-methyl-pyrazolo[1,5-a]pyrazin-4-yl)-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester (281 mg, 805.56 umol), 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole (251.41 mg, 1.21 mmol), Pd(dppf)Cl2CH2Cl2 (65.79 mg, 80.56 umol), K2CO3 (334.01 mg, 2.42 mmol) and water (0.3 mL) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was filtered through celite and concentrated. The residue was purified by silica gel column chromatography (HE / EA 0-100%) to give tert-butyl 4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (325 mg, 823.89 umol, 102% yield) as a light yellow gel. LCMS (ESI+): C 21 H 27 m / z calculated for N6O2 [M+H] + , 395.2; experimental value, 395.3. Rt = 0.85min.

[0444] 3. Preparation of 3-methyl-6-(1-methylpyrazol-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyrazine

[0445]

[0446] To tert-butyl 4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridine-1-carboxylate (325 mg, 823.89 umol) in DCM (2 mL) was added TFA (744.50 mg, 6.53 mmol, 0.5 mL) and stirred for 16 h. After concentration, the crude residue was used as is in the next step. LCMS (ESI+): C16 H 19 m / z calculated for N6 [M+H] + , 295.2; experimental value, 295.1. Rt = 0.49min.

[0447] 4. Preparation of 3-methyl-6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyrazine

[0448]

[0449] Pd(OH)2 / C (118.64 mg, 168.96 umol, 20% purity) was added to 3-methyl-6-(1-methylpyrazol-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)pyrazolo[1,5-a]pyrazine (690 mg, 1.69 mmol, TFA salt) in MeOH (6 mL) and stirred at 60 psi for 16 h under H2. After filtration through celite, the concentrated residue was used as is in the next step. LCMS (ESI+): C 16 H 21 m / z calculated for N6 [M+H] + , 297.2; experimental value, 297.2. Rt = 0.41min.

[0450] 5. Preparation of 1-[4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0451]

[0452] To DCM (4 mL) containing 3-methyl-6-(1-methylpyrazol-4-yl)-4-(4-piperidinyl)pyrazolo[1,5-a]pyrazine (226 mg, 762.56 umol) was added TEA (154.33 mg, 1.53 mmol, 212.57 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (82.82 mg, 915.08 umol, 74.35 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) and preparative HPLC to give 1-[4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one (26.5 mg, 75.62 umol, 9.9% yield) as a white solid. LCMS (ESI+): C 19H 23 m / z calculated for N6O [M+H] + , 351.2; experimental value, 351.1. Rt = 0.61min. 1 H NMR(400MHz, CDCl3,d):8.34-8.37(m,1H),7.88-7.90(m,1H),7.86-7.88(m, 1H),7.76-7.78(m,1H),6.63-6.71(m,1H),6.31-6.37(m,1H),5.72-5.76(m,1 H),4.79-4.89(m,1H),4.17-4.26(m,1H),3.98-4.00(m,3H),3.50-3.58(m,1H ),3.28-3.37(m,1H),2.90-3.00(m,1H),2.53-2.56(m,3H),2.02-2.12(m,4H)

[0453] Example 10 .1-[4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one

[0454]

[0455] 1-[4-[3-methyl-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-3,6-dihydro-2H-pyridin-1-yl]prop-2-en-1-one (20 mg, 54.53 umol, 95% purity) was isolated as a white solid as a side product from Example 9. LCMS (ESI+): C 19 H 21 m / z calculated for N6O [M+H] + , 349.2; experimental value, 349.2. Rt = 0.57min. 1 H NMR(400MHz, CDCl3,d):8.41-8.47(m,1H),7.97-8.05(m,1H),7.87-7.92(m,1H),7.81-7.84(m,1H),6.62-6.76(m,1H),6.33-6 .43(m,1H),6.01-6.15(m,1H),5.75-5.83(m,1H),4.35-4.50(m,2H),3.88-4.09(m,5H),2.77-2.92(m,2H),2.29-2.37(m,3H).

[0456] Embodiment 11.1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]prop-2-en-1-one

[0457]

[0458] 1. Preparation of tert-butyl 3-(trifluoromethylsulfonyloxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate

[0459]

[0460] 3-Oxo-8-azabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (300 mg, 1.33 mmol) was cooled to -78 ° C and potassium [bis(trimethylsilyl)amide] (1 M, 1.41 mL) was added dropwise. After stirring at 0 ° C for 2 h, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (713.60 mg, 2.00 mmol) was added in one go. The mixture was allowed to warm to room temperature overnight. NH4Cl (saturated) was added and extracted with EA. The organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by silica gel column chromatography (EA / Hept. (0-100%) to give tert-butyl 3-(trifluoromethylsulfonyloxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (473 mg, 1.32 mmol, 99% yield) as a colorless oil.

[0461] 2. Preparation of tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate

[0462]

[0463] To a solution of tert-butyl 3-(trifluoromethylsulfonyloxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (573 mg, 1.60 mmol) and 4,4,5,5-tetramethyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1,3,2-dioxaborolan (814.38 mg, 3.21 mmol) in dioxane (5 mL) was added Pd(dppf)Cl2 DCM (130.95 mg, 160.35 umol) and KOAc (472.10 mg, 4.81 mmol). The mixture was stirred at 90 °C under N2 for 12 h. After filtration through celite, the reaction mixture was concentrated under vacuum to give the crude material, which was purified by silica gel column chromatography (PE / EA=7 / 3) to give tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (372 mg, 1.11 mmol, 69% yield) as a colorless oil.

[0464] 3. Preparation of tert-butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate

[0465]

[0466] Water (0.5 mL) and dioxane (3 mL) containing 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (200 mg, 855.96 umol), tert-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (430.43 mg, 1.28 mmol), K2CO3 (354.91 mg, 2.57 mmol), tetrakis(triphenylphosphine)palladium(0) (197.82 mg, 171.19 umol) were degassed and heated to 95° C. for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc and filtered through celite. The concentrated residue was purified by silica gel column chromatography (EtOAc / DCM 0-100%) to give tert-butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (372 mg, 915.17 umol, 106% yield) as a white solid. LCMS (ESI+): C 22 H 27 m / z calculated for N6O2 [M+H] +, 407.2; experimental value, 407.3. Rt = 0.99min.

[0467] 4. Preparation of 4-(8-azabicyclo[3.2.1]oct-2-en-3-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine

[0468]

[0469] To tert-butyl 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate (376 mg, 925.01 umol) in DCM was added TFA (105.47 mg, 925.01 umol, 70.83 uL) and stirred at room temperature for 1 h. The crude material was concentrated and used as is in the next step. LCMS (ESI+): C 17 H 19 m / z calculated for N6 [M+H] + , 307.2; experimental value, 307.1. Rt = 0.64min.

[0470] 5. Preparation of 4-(8-azabicyclo[3.2.1]oct-3-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine

[0471]

[0472] Pd(OH)2 / C (220.49 mg, 314.01 umol, 20% purity) was added to MeOH (6 mL) containing 4-(8-azabicyclo[3.2.1]oct-2-en-3-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (481 mg, 1.57 mmol) and stirred at room temperature for 16 h under H2 at 60 psi. After filtration through celite, the concentrated residue was used as is in the next step. LCMS (ESI+): C 17 H 21 m / z calculated for N6 [M+H] + , 309.2; experimental value, 309.1. Rt = 0.47min.

[0473] 6. Preparation of 1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]prop-2-en-1-one

[0474]

[0475] To DCM (5 mL) containing 4-(8-azabicyclo[3.2.1]oct-3-yl)-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (446 mg, 1.06 mmol, TFA) was added TEA (214.20 mg, 2.12 mmol, 295.04 uL) and stirred for 5 min. After cooling to 0 ° C, acryloyl chloride (114.95 mg, 1.27 mmol, 103.19 uL) was added and stirred for 3 min. The reaction was quenched with saturated NaHCO3 aqueous solution and extracted with DCM. The organic layer was dried over Na2SO4 and the concentrated residue was purified by silica gel column chromatography (EtOAc / MeOH 0-15%) and preparative HPLC to give 1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-8-azabicyclo[3.2.1]oct-8-yl]prop-2-en-1-one (45.3 mg, 118.74 umol, 11% yield, 95% purity) as a white solid. LCMS (ESI+): C 20 H 23 m / z calculated for N6O [M+H] + , 363.2; experimental value, 363.2. Rt=0.60min. 1 H NMR(400MHz, CDCl3,d):8.44-8.47(m,1H),7.99-8.06(m,1H),7.92-7.98(m,1H),7.86-7.90(m,1H),6.64-6.77(m,1H),6 .55-6.63(m,1H),6.43-6.51(m,1H),5.72-5.80(m,1H),4.82-5.00(m,1H),4.42-4.58(m,1H),3.98-4.04(m,3H),3.92(br s,1H),1.86-3.00(m,8H).

[0476] Example 12 .1-[2-Methyl-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0477]

[0478] 1-[2-methyl-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one was prepared in a similar manner to Example 1, but starting from tert-butyl 2-methyl-4-oxo-piperidine-1-carboxylate. Weight: 22.6 mg, 95% purity, as a white solid. LCMS (ESI+): C 19 H 23 m / z calculated for N6O [M+H] + , 351.2; experimental value, 351.1. Rt = 0.61min. 1 H NMR(400MHz, CDCl3,d):8.43-8.47(m,1H),7.96-8.01(m,1H),7.87-7.93(m,2H),6.71-6.79(m,1H),6 .60-6.69(m,1H),6.37-6.44(m,1H),5.70-5.77(m,1H),4.20-4.56(m,2H),3.98-4.03(m,3H),3.49(br s,1H),3.33-3.43(m,1H),2.19-2.34(m,2H),2.02-2.14(m,2H),1.16-1.28(m,3H).

[0479] Example 13 .1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-9-azabicyclo[3.3.1]non-9-yl]prop-2-en-1-one

[0480]

[0481] 1-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-9-azabicyclo[3.3.1]non-9-yl]prop-2-en-1-one was prepared in a similar manner to Example 1, but starting from tert-butyl 3-oxo-9-azabicyclo[3.3.1]nonane-9-carboxylate. Weight: 96 mg, 95% purity, as a white solid. LCMS (ESI+): C 21 H 25 m / z calculated for N6O [M+H] + , 377.2; experimental value, 377.3. Rt = 0.66min. 1H NMR(400MHz, CDCl3,d):8.43(s,1H),7.84-8.01(m,3H),6.72-6.80(m,1H),6.59-6.72(m,1H),6.30-6.42(m,1H),5.67-5.79(m,1H), 5.04-5.24(m,1H),4.35-4.54(m,1H),3.96-4.02(m,3H),2.98-3.13(m,1H),2.32-2.53(m,2H),1.85-2.21(m,4H),1.55-1.84(m,4H).

[0482] Embodiment 14 .1-[5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-azabicyclo[2.2.2]oct-2-yl]prop-2-en-1-one

[0483]

[0484] 1-[5-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-2-azabicyclo[2.2.2]oct-2-yl]prop-2-en-1-one was prepared in a similar manner to Example 1, but starting from tert-butyl 5-oxo-2-azabicyclo[2.2.2]octane-2-carboxylate. Weight: 4.9 mg, 95% purity, as a white solid. LCMS (ESI+): C 20 H 23 m / z calculated for N6O [M+H] + , 363.2; experimental value, 363.2. Rt=0.62min. 1 H NMR (400MHz, CDCl3, δ): 8.44-8.51(m,1H),7.85-8.04(m,3H),6.68-6.76(m,1H),6.54-6.67(m,1H),6.34-6.49(m,1H ),5.57-5.75(m,1H),4.17-4.24(m,1H),3.99-4.04(m,3H),3.53-3.85(m,2H),2.14-3.00(m,3H),1.44-1.97(m,5H).

[0485] Embodiment 15 .1-[3-methyl-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one

[0486]

[0487] 1-[3-methyl-4-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1-piperidinyl]prop-2-en-1-one was prepared in a similar manner to Example 1, but starting from tert-butyl 3-methyl-4-oxo-piperidine-1-carboxylate. Weight: 51 mg, 95% purity, as a white solid. LCMS (ESI+): C 19 H 23 m / z calculated for N6O [M+H] + , 351.2; experimental value, 351.1. Rt = 0.61min. 1 H NMR (400MHz, CDCl3, δ): 8.45-8.48(m,1H),7.97-8.00(m,1H),7.86-7.96(m,2H),6.75-6.79(m,1H),6.58-6.71(m,1H),6.31-6 .39(m,1H),5.69-5.77(m,1H),3.99-4.02(m,3H),3.03-3.71(m,4H),2.25-2.68(m,3H),1.87-1.96(m,1H),0.75-0.85(m,3H).

[0488] Examples 16-19

[0489]

[0490] 1. Preparation of racemic 3-(methylamino)cyclopentan-1-ol

[0491]

[0492] LAH (1.14 g, 30.11 mmol, 2 eq.) was added to THF (100 mL) containing racemic-(3-oxocyclopentyl)carbamic acid tert-butyl ester (3 g, 15.06 mmol, 1 eq.) at 0 ° C under N2. The mixture was then heated to 70 ° C and stirred at 70 ° C for 2.5 h. TLC (PE / EtOAc=1 / 1) showed that the starting material was completely consumed and a new more polar spot was detected. Water (5 mL) was added dropwise and Na2SO4 (3 g) was added to the mixture. The mixture was filtered and the filtrate was concentrated to give racemic-3-(methylamino)cyclopentan-1-ol (1.7 g, crude) as a colorless oil. 1H NMR: (400MHz, CDCl3) δ = 4.37-4.14 (m, 1H), 3.24-3.08 (m, 1H), 2.32 (d, J = 5.6Hz, 3H),2.06-1.91(m,1H),1.88-1.72(m,2H),1.65-1.46(m,2H),1.39-1.26(m,1H).

[0493] 2. Preparation of racemic-(3-hydroxycyclopentyl)(methyl)carbamic acid tert-butyl ester

[0494]

[0495] DCM (50 mL) containing racemic-3-(methylamino)cyclopentan-1-ol (1.7 g, 14.76 mmol, 1 eq.), DIEA (3.82 g, 29.52 mmol, 5.14 mL, 2 eq.) and Boc2O (6.44 g, 29.52 mmol, 2 eq.) was stirred at 20°C for 12 h. TLC (PE / EtOAc=1 / 1) showed that the starting material was completely consumed and a new less polar spot was found. LCMS showed that the desired MS was detected. Water (30 mL) was added and the mixture was extracted with DCM (60 mL x 3). The organics were dried over Na2SO4, filtered and concentrated to give a crude material which was purified by silica gel column chromatography eluting with 0% to 50% to 80% EtOAc / PE to give rac-tert-butyl (3-hydroxycyclopentyl)(methyl)carbamate (2.8 g, 13.01 mmol, 88.11% yield) as a colorless oil. LCMS: (M+H) + -56:160.1). 1 H NMR: (400MHz, CDCl3) δ = 4.78-4.31 (m, 1H), 4.26-4.13 (m, 1H), 2.84-2.68 (m, 3H), 1.90-1.73 (m, 4H), 1.64-1.54 (m, 2H), 1.47-1.41 (m, 9H).

[0496] 3. Preparation of racemic tert-butyl methyl (3-oxocyclopentyl) carbamate

[0497]

[0498] DMP (8.27 g, 19.51 mmol, 1.5 equiv) was added to a mixture of racemic-(3-hydroxycyclopentyl)(methyl)carbamic acid tert-butyl ester (2.8 g, 13.01 mmol, 1 equiv) in DCM (10 mL) at 20 ° C under N2. The mixture was stirred at 20 ° C for 16 h. Many white solids were isolated. TLC (PE / EtOAc=3 / 1) showed that the starting material was completely consumed and new smaller spots were found. The mixture was filtered and the filtrate was washed with water (30 mL x 2), brine (30 mL), dried over Na2SO4, filtered and the filtrate was concentrated to give a crude material, which was purified by silica gel column chromatography, eluted with 0% to 30% EtOAc / PE to give racemic-methyl (3-oxocyclopentyl) carbamic acid tert-butyl ester (2.3 g, 10.78 mmol, 82.92% yield) as a colorless oil. 1 H NMR: (400MHz, CDCl3) δ = 4.69 (s, 1H), 2.77 (s, 3H), 2.47-2.33 (m, 2H), 2.28-2.14 (m, 3H), 1.99-1.91 (m, 1H), 1.45 (s, 9H).

[0499] 4. Preparation of racemic-(Z)-methyl(3-(2-toluenesulfonylhydrazono)cyclopentyl)carbamic acid tert-butyl ester

[0500]

[0501] At 20 ° C, tert-butyl methyl (3-oxocyclopentyl) carbamate (1 g,

[0502] To a solution of (4.69 mmol, 1 eq.) in MeOH (10 mL) was added TsNHNH2 (873.21 mg, 4.69 mmol, 1 eq.). The mixture was stirred at 20 °C for 40 min. LCMS showed complete consumption of the starting material and a major peak with the desired MS was detected. The solvent was removed below 25 °C to give crude racemic-(Z)-methyl(3-(2-tosylhydrazono)cyclopentyl)carbamic acid tert-butyl ester (1.7 g, crude) as a colorless oil. LCMS: (M+H + :326.1).

[0503] 5. Preparation of tert-butyl methyl (3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-carbonyl)cyclopentyl)carbamate

[0504]

[0505] To a solution of tert-butyl rac-(Z)-methyl(3-(2-tosylhydrazono)cyclopentyl)carbamate (1.7 g, 4.46 mmol, 1 eq) in dioxane (30 mL) was added CsCO (4.36 g, 13.37 mmol, 3 eq) at 20°C. Compound 6 (1.62 g, 7.13 mmol, 1.6 eq) was then slowly added to the mixture at 20°C. The mixture was then stirred at 110°C under N for 16 h. LCMS showed that several peaks were detected and a peak with the desired MS was found. The solvent was removed to give a crude material which was purified by silica gel column chromatography eluting with 0% to 50% to 100% EtOAc / PE to give tert-butyl methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-carbonyl)cyclopentyl)carbamate (302 mg, 0.604 mmol, 13.57% yield, 85% purity) as a colorless oil. LCMS: (M+H + :425.2). 1 H NMR: (500MHz, CDCl3)δ=8.73-8.69(m,1H),8.14-8.11(m,1H),8.00-7.92(m,2H),7.46-7.44(m,1H),4.63-4.35(m,2H),4.17-4 .09(m,1H),4.03-4.00(m,3H),3.86-3.73(m,1H),2.86-2.78(m,3H),2.23-2.14(m,1H),1.99-1.84(m,3H),1.49-1.47(m,9H).

[0506] 6. Preparation of racemic-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)(3-(methylamino)cyclopentyl)methanone hydrochloride

[0507]

[0508] To a mixture of tert-butyl methyl (3- (6- (1-methyl -1H- pyrazol-4-yl) pyrazolo [1,5-a] pyrazine -4- carbonyl) cyclopentyl) carbamate (302 mg, 0.711 mmol, 1 equiv) in DCM (1 mL) was added EtOAc (4M, 6 mL) containing HCl. The mixture was stirred at 25 ° C for 1 hour. LCMS showed that the starting material was completely consumed and a peak with the desired MS was detected. The reaction mixture was concentrated to give rac- (6- (1-methyl -1H- pyrazol-4-yl) pyrazolo [1,5-a] pyrazine -4-yl) (3- (methylamino) cyclopentyl) ketone hydrochloride (230 mg, 0.709 mmol, 99.66% yield) as a yellow solid, which was used directly in the next step. LCMS: (M+H + :325.1).

[0509] 7. Preparation of racemic-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-carbonyl)cyclopentyl)acrylamide

[0510]

[0511] To a mixture of rac-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)(3-(methylamino)cyclopentyl)methanone hydrochloride (230 mg, 0.709 mmol, 1 eq) and DIEA (274.92 mg, 2.13 mmol, 3 eq) in DCM (15 mL) at 0°C was added compound 9 (64.17 mg, 0.709 mmol, 1 eq). The mixture was stirred at 0°C for 2 min. LCMS showed complete consumption of the starting material and a peak with the desired MS was detected. MeOH (1 mL) was added dropwise. The resulting mixture was stirred at 25°C for 10 min. The solvent was removed to give a crude material which was purified by preparative HPLC (column: Welch Xtimate C18 150x25mm x 5um; conditions: water (NH4HCO3)-ACN, start B35, end B 55, gradient time (min) 12, 100% B hold time (min) 2, flow rate (mL / min) 25) to give racemic-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-carbonyl)cyclopentyl)acrylamide (200 mg, 0.528 mmol, 74.54% yield) as a white solid. LCMS: (M+H + :379.1).

[0512] 8. General Procedure for Isolation of N-Methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-carbonyl)cyclopentyl)acrylamide

[0513]

[0514] N-Methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-carbonyl)cyclopentyl)acrylamide (120 mg, 0.305 mmol, 1 eq.) as a mixture of diastereomers was separated by SFC (column: DAICEL CHIRALPAK IG (250 mm x 30 mm, 10 um); conditions: 0.1% NH3H2O ​​MeOH, start B 55%, end B 55%, gradient time (min), 100% B hold time (min), flow rate (mL / min) 80) to give Example 16 (15.2 mg, Rt = 2.256 min) as a yellow solid and a mixture of Example 17 and Example 18 (40 mg) as a yellow solid and impure Example 19 (17 mg). The mixture of Example 17 and Example 18 (40 mg) was further separated by SFC (column: DAICEL CHIRALPAK IG (250 mm x 30 mm, 10 um); conditions: 0.1% NH3H2O ​​EtOH, start B 60%, end B 60%, gradient time (min), 100% B hold time (min), flow rate (mL / min) 80) to give Example 17 (11.6 mg, Rt = 2.437 min) as a yellow solid and Example 18 (12.6 mg, Rt = 2.409 min) as a yellow solid. Impure Example 19 (17 mg) was further purified by preparative HPLC (column: Waters XbridgeBEH C18 100x25mm x 5um; conditions: water (FA)-ACN, start B 20, end B 40, gradient time (min) 12, 100% B hold time (min) 2, flow rate (mL / min) 25) to give Example 19 (11.6 mg, Rt = 2.630 min) as a yellow solid.

[0515] Example 16 Spectrum of:

[0516]

[0517] LCMS: (M+H + :379.3).HPLC:(purity:100%).SFC:(ee:96.64%). 1H NMR: (500MHz, METHANOL-d4)δ=8.96(s,1H),8.14(s,1H),8.06(s,1H),7.99(s,1H),7.32(d,J=1.5Hz,1H),6.80-6.59(m,1H),6.09(t,J=17.5Hz ,1H),5.66-5.63(m,1H),4.99-4.88(m,0.5H),4.57-4.46(m,1.5H),3.9 3-3.86(m,3H),3.04-2.85(m,3H),2.29-2.09(m,2H),2.06-1.74(m,4H).

[0518] Embodiment 17 Spectrum of:

[0519]

[0520] LCMS: (M+H + :379.3).HPLC:(purity:100%).SFC:(ee:99.26%). 1 H NMR: (500MHz, METHANOL-d4)δ=8.94(s,1H),8.13(s,1H),8.05(d,J=2.0Hz,1H ),7.97(s,1H),7.31(s,1H),6.86-6.59(m,1H),6.11(t,J=18.5Hz,1H),5.66- 5.63(m,1H),5.12-4.99(m,0.5H),4.66-4.54(m,0.5H),4.42(d,J=5.5Hz,1H) ,3.94-3.83(m,3H),3.04-2.82(m,3H),2.18-2.00(m,2H),1.99-1.63(m,4H).

[0521] Embodiment 18 Spectrum of:

[0522]

[0523] LCMS: (M+H + :379.3).HPLC:(purity:100%).SFC:(purity:100%). 1H NMR: (500MHz, METHANOL-d4)δ=8.96(s,1H),8.14(s,1H),8.06(s,1H),7.99(s,1H),7.32(d,J=1.5Hz,1H),6.80-6.59(m,1H),6.09(t,J=17.5Hz ,1H),5.66-5.63(m,1H),4.99-4.88(m,0.5H),4.57-4.46(m,1.5H),3.9 3-3.86(m,3H),3.04-2.85(m,3H),2.29-2.09(m,2H),2.06-1.74(m,4H).

[0524] Embodiment 19 Spectrum of:

[0525]

[0526] LCMS: (M+H + :379.3).HPLC:(purity:100%).SFC:(purity:97.26%). 1 H NMR: (500MHz, METHANOL-d4)δ=8.94(s,1H),8.13(s,1H),8.05(d,J=2.0Hz,1H ),7.97(s,1H),7.31(s,1H),6.86-6.59(m,1H),6.11(t,J=18.5Hz,1H),5.66- 5.63(m,1H),5.12-4.99(m,0.5H),4.66-4.54(m,0.5H),4.42(d,J=5.5Hz,1H) ,3.94-3.83(m,3H),3.04-2.82(m,3H),2.18-2.00(m,2H),1.99-1.63(m,4H).

[0527] Examples 20-23

[0528]

[0529] 1. Preparation of racemic 3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopent-3-ene-1-carboxylic acid methyl ester

[0530]

[0531] A mixture of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (1 g, 4.28 mmol, 1.00 equiv), methyl cyclopent-3-ene-1-carboxylate (971.83 mg, 7.70 mmol, 1.80 equiv), Pd(dba)2 (246.09 mg, 427.98 μmol, 0.10 equiv), XPhos (306.04 mg, 641.97 μmol, 0.15 equiv) and N,N-dicyclohexylmethylamine (1.67 g, 8.56 mmol, 2.00 equiv) in dioxane (24 mL) was bubbled with N2 for 1 min. The mixture was then stirred at 100 °C for 16 h. LCMS showed complete consumption of the starting material and a major peak with the desired MS was detected. The mixture was cooled to 15 °C and the solvent was removed to give a residue which was purified by silica gel column chromatography eluting with 0% to 50% to 100% EtOAc / PE to give rac-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopent-3-ene-1-carboxylic acid methyl ester (1.3 g, 93.94% yield) as an orange oil. LCMS: (M+H + :324.3). 1 H NMR: (400MHz, METHANOL-d4) δ = 8.61 (s, 1H), 8.07 (s, 1H), 7.98-7.94 (m, 2H), 6.92-6.86 (m, 1H), 6.09-5.94(m,1H),4.10-3.91(m,6H),3.74-3.70(m,3H),3.11-3.06(m,1H),2.68-2.66(m,1H).

[0532] 2. Preparation of racemic 3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxylic acid methyl ester

[0533]

[0534] To a solution of rac-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopent-3-ene-1-carboxylic acid methyl ester (700.00 mg, 2.16 mmol, 1.00 equiv) in MeOH (60 mL) was added Pd / C (230.38 mg, 216.48 μmol, 10% purity, 0.10 equiv) at 20 °C. The mixture was stirred under H2 at 20 °C and 15 psi for 8 hours. LCMS showed complete consumption of the starting material and a major peak with the desired MS was detected. The reaction mixture was filtered and concentrated under vacuum to give crude rac-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxylic acid methyl ester (540 mg, crude), which was used directly in the next step. LCMS (M+H + :326.1).

[0535] 3. Preparation of racemic 3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxylic acid

[0536]

[0537] To a solution of rac-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxylic acid methyl ester (1.00 g, 3.07 mmol, 1.00 equiv) in MeOH (30 mL) and water (10 mL) was added NaOH (147.52 mg, 3.69 mmol, 1.20 equiv) at 25 °C. The reaction mixture was stirred at 25 °C for 8 hours. LCMS showed that the starting material was completely consumed. HCl (2M, 2 mL) was added to the reaction mixture at 25 °C to adjust to pH = 5-6. The crude material was concentrated under vacuum to give crude rac-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxylic acid (950 mg, crude) as a yellow solid. LCMS: (M+H + :312.1).

[0538] 4. Preparation of racemic-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxamide

[0539]

[0540] To a solution of rac-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxylic acid (950 mg, 3.05 mmol, 1.00 equiv) in DCM (40 mL) was added DIEA (1.18 g, 9.15 mmol, 3.00 equiv) at 25 °C. The mixture was stirred at 25 °C for 10 min. Then, compound 7 (247.22 mg, 3.66 mmol, hydrochloride, 1.20 equiv) and HATU (1.40 g, 3.66 mmol, 1.20 equiv) were added at 25 °C. The reaction mixture was stirred at 25 °C for 1 hour. LCMS indicated complete consumption of the starting material and a major peak with the desired MS was detected. The reaction mixture was concentrated to give a crude material which was purified by silica gel column chromatography eluting with 0% to 100% EtOAc / PE to give rac-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxamide (900 mg, 90.93% yield) as a yellow oil. LCMS: (M+H + :325.2). 1 H NMR (400MHz, METHANOL-d4) δ = 8.62 (s, 1H), 8.15-8.12 (m, 1H), 7.99-7.95 (m, 2H), 6.94-6.92 (m,1H),3.93(s,3H),3.74-3.69(m,1H),2.95(s,1H),2.74-2.72(m,3H),2.36-2.11(m,6H).

[0541] 5. Preparation of racemic-N-methyl-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)hexamethylenetetramine

[0542]

[0543] To a solution of rac-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentane-1-carboxamide (200 mg, 616.56 μmol, 1.00 equiv) in THF (10 mL) was added BH3·THF (1 M, 3.08 mL, 5.00 equiv) at 0°C. The ice bath was removed and the reaction mixture was stirred at 35°C for 2 hours. LCMS indicated complete consumption of the starting material and a major peak with the desired MS was detected. The reaction mixture was quenched with MeOH (3 mL). The mixture was concentrated to give crude rac-N-methyl-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)hexamethylenetetramine (130.00 mg, crude) which was used directly in the next step. LCMS: (M+H + :311.2).

[0544] 6. Preparation of tert-butyl methyl ((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)carbamate

[0545]

[0546] To a mixture of rac-N-methyl-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)hexamethylenetetramine (130 mg, 418.82 μmol, 1.00 equiv) in MeOH (15 mL) was added DIEA (162.38 mg, 1.26 mmol, 3.00 equiv). The reaction mixture was stirred at 25 °C for 10 min. Then, Boc2O (137.11 mg, 628.23 μmol, 1.50 equiv) was added at 25 °C. The reaction mixture was stirred at 25 °C for 10 min. LCMS showed complete consumption of the starting material and a peak with the desired MS was detected. The solvent was removed to give the crude material which was purified by silica gel column chromatography eluting with 0% to 100% EtOAc / PE to give tert-butyl methyl((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)carbamate (130 mg, 75.61% yield) as a yellow oil. LCMS: (M+H + :411.3). 1H NMR: (400MHz, METHANOL-d4)δ=8.62(s,1H),8.11(s,1H),8.00-7.96(m,2H),6.91(s,1H),3.94-3.93(m,3 H),3.81(s,2H),2.88(s,3H),2.60-2.46(m,1H),2.25-2.16(m,4H),1.91-1.73(m,3H),1.45-1.43(m,9H).

[0547] 7. Preparation of racemic-N-methyl-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)hexamethylenetetramine hydrochloride

[0548]

[0549] To a solution of tert-butyl methyl ((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)carbamate (280 mg, 682.08 μmol, 1.0 equiv) in DCM (10 mL) at 20 °C was added HCl / EA (4M, 10 mL) and the reactants were stirred at 20 °C for 30 min. LCMS showed complete consumption of the starting material and a peak with the desired MS was detected. The mixture was concentrated under vacuum to give rac-N-methyl-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)hexamethylenetetramine hydrochloride (220 mg, crude) as a yellow oil. LCMS: (M+H + :311.3).

[0550]

[0551] 8. Preparation of racemic-N-methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide

[0552] To a mixture of rac-N-methyl-1-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)hexamethylenetetramine hydrochloride (220 mg, 708.77 μmol, 1.0 eq) and DIPEA (183.20 mg, 1.42 mmol, 2.0 eq) in DCM (20 mL) was added compound 12 (70.56 mg, 779.65 μmol, 1.1 eq) at 0°C. The mixture was stirred at 0°C for 10 min. LCMS showed complete consumption of the starting material. MeOH (3 mL) was added dropwise. The reaction mixture was concentrated to give rac-N-methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide (220 mg, crude) as a yellow oil. LCMS: (M+H + :365.3.).

[0553]

[0554] 9. General Procedure for the Isolation of Racemic-N-Methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide

[0555] Racemic-N-methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide (220.00 mg, 603.66 μmol, 1.0 equiv) was separated by SFC (column: DAICELCHIRALPAK AD (250 mm x 30 mm, 10 μm); conditions: 0.1% NH3H2O ​​EtOH, start B 45%, end B 45%, flow rate (mL / min) 70.), to give N-methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide (100 mg, 45.45% yield) as a mixture of two isomers as a yellow solid, Example 22 (45.8 mg, 19.68% yield) as a yellow solid, and Example 23 (42.7 mg, 18.85% yield) as a yellow solid.

[0556]

[0557] 10. General Procedure for the Isolation of Racemic-N-Methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide

[0558] N-Methyl-N-((3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclopentyl)methyl)acrylamide (100.00 mg, 274.39 μmol, 1.0 equiv) as a mixture of two isomers was separated by SFC (column: Phenomenex-Cellulose-2 (250 mm x 30 mm, 10 μm); conditions: 0.1% NH3H2O ​​EtOH, start B 45, end B45, flow rate (mL / min) 80.) to give Example 20 (33.4 mg, 33.40% yield) as a yellow solid and Example 21 (35.8 mg, 35.80% yield) as a yellow solid.

[0559] Embodiment 20 Spectrum of:

[0560]

[0561] LCMS: (M+H + :365.2).HPLC:(purity:100.00%).SFC:(ee:100.00%). 1 H NMR: (400MHz, METHANOL-d4) δ = 8.62 (d, J = 4.4Hz, 1H), 8.11 (d, J = 8.4Hz, 1H), 8.04-7.91 (m, 2H), 6.96-6.72 (m, 2H), 6.31-6.19 (m, 1H), 5.80-5.69 (m, 1 H),3.95(s,3H),3.89-3.80(m,1H),3.71-3.39(m,2H),3.18-3.03(m,3H),2 .66-2.51(m,1H),2.38-2.00(m,4H),1.91-1.80(m,1H),1.59-1.43(m,1H).

[0562] Embodiment 21 Spectrum of:

[0563]

[0564] LCMS: (M+H + :365.2).HPLC:(purity:100.00%).SFC:(ee:100.00%). 1H NMR: (500MHz, METHANOL-d4) δ = 8.84 (d, J = 3.5Hz, 1H), .42-8.16 (m, 3H), 7.16-6.89 (m, 2H), 6.43-6.31 (m, 1H), 5.96-5.74 (m, 1H), 4. 17-4.09(m,3H),4.00-3.69(m,3H),3.36-3.17(m,3H),2.77-2.67(m,1H),2.48-2.32(m,3H),2.16-2.04(m,2H),1.88-1.73(m,1H).

[0565] Embodiment 22 Spectrum of:

[0566]

[0567] LCMS: (M+H + :365.2).HPLC:(purity:94.52%).SFC:(ee:99.04%). 1 H NMR: (400MHz, METHANOL-d4) δ = 8.64 (d, J = 6.4Hz, 1H), 8.24-7.91 (m, 3H), 6.95-6.70 (m, 2H), 6.23-6.16 (m, 1H), 5.76-5.58 (m, 1H) ,3.96(s,3H),3.82-3.50(m,3H),3.21-2.96(m,3H),2.61-2.50(m,1H),2.34-2.09(m,3H),2.00-1.83(m,2H),1.69-1.57(m,1H).

[0568] Embodiment 23 Spectrum of:

[0569]

[0570] LCMS: (M+H + :365.2).HPLC:(purity:97.13%).SFC:(ee:100.00%). 1H NMR: (400MHz, METHANOL-d4) δ = 8.62 (d, J = 4.4Hz, 1H), 8.11 (d, J = 8.4Hz, 1H), 8.06-7.83 (m, 2H), 6.98-6.69 (m, 2H), 6.31-6.18 (m, 1H), 5.77-5.72 (m, 1 H),3.94(s,3H),3.88-3.79(m,1H),3.69-3.39(m,2H),3.21-2.94(m,3H),2 .72-2.58(m,1H),2.37-2.01(m,4H),1.91-1.76(m,1H),1.57-1.45(m,1H).

[0571] Examples 24-27

[0572]

[0573] 1. Preparation of tert-butyl (3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohex-2-en-1-yl)carbamate

[0574]

[0575] A mixture of 4-chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (300.00 mg, 1.28 mmol, 1.0 equiv), rac-(R)-tert-butyl(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)cyclohex-2-en-1-yl)carbamate (700.00 mg, 1.30 mmol, 1.0 equiv), KCO (532.36 mg, 3.85 mmol, 3.0 equiv), Pd(dtbpf)Cl (83.68 mg, 128.39 μmol, 0.1 equiv) in dioxane (10 mL) / water (2 mL) was bubbled with N for 1 min and the reaction was stirred at 90 °C for 2 h. LCMS showed complete consumption of the starting material. The reaction mixture was concentrated to give a crude material which was purified by silica gel column chromatography (PE to PE / EA = 1 / 1 to EA) to give tert-butyl (R)-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohex-2-en-1-yl)carbamate (350.00 mg, 62.19% yield) as a yellow solid. LCMS: (M+H + :395.7).

[0576] 2. Preparation of racemic-((1R,3S)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester

[0577]

[0578] To a mixture of rac-(R)-tert-butyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohex-2-en-1-yl)carbamate (610.00 mg, 1.55 mmol, 1.0 equiv) in MeOH (30 mL) was added Pd / C (700.00 mg, 6.58 mmol) at 15°C. The reaction was stirred at 50°C under H2 (50 psi) for 24 h. LCMS showed complete consumption of the starting material and a peak with the desired MS was detected. The mixture was filtered to remove Pd / C and concentrated under vacuum to remove MeOH to give tert-butyl rac-((1R,3S)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamate (550.00 mg, crude) as a yellow oil. LCMS: (M+H + :397.2).

[0579] 3. Preparation of tert-butyl methyl (3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamate

[0580]

[0581] To a solution of tert-butyl rac-((1R,3S)-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamate (600.00 mg, 1.51 mmol, 1.0 equiv) in DMF (10 mL) was added NaH (181.60 mg, 4.54 mmol, 60% purity, 3.0 equiv) at 0°C. The reaction mixture was stirred at 0°C for 30 min. CHI (644.39 mg, 4.54 mmol, 3.0 equiv) was then added to the mixture at 0°C. The reaction mixture was stirred at 20°C for 6 hours. LCMS showed that the desired MS was detected and the starting material was completely consumed. The reaction mixture was quenched with MeOH (5 mL). The reaction mixture was removed to give a crude material which was purified by preparative HPLC (column: Waters XbridgeBEH C18 100x25mm x 5μm; conditions: water (0.225% FA)-ACN, start B 38, end B 68, gradient time (min) 12, 100% B holding time (min) 2, flow rate (mL / min) 25.), to give racemic-cis-methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester (200 mg, 26.40% yield) as a white solid, racemic-trans-methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester (150 mg, 22.94% yield) as a white solid.

[0582] Racemic-cis-methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester: LCMS: (M+H + :411.8).

[0583] Racemic-trans-methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester: LCMS: (M+H + :411.8.).

[0584] 4. Preparation of racemic-trans-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1-amine hydrochloride

[0585]

[0586] To a solution of rac-trans-methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester (150.00 mg, 365.40 μmol, 1.0 equiv) in DCM (2 mL) at 20 °C was added HCl / EA (4M, 15.00 mL) and the reactants were stirred at 20 °C for 30 min. LCMS showed that the starting material was completely consumed and a peak with the desired MS was detected. The mixture was concentrated under vacuum to give rac-trans-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1-amine hydrochloride (90.00 mg, crude) as a yellow oil. LCMS: (M+H + :311.3).

[0587] 5. Preparation of racemic-trans-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide

[0588]

[0589] To a mixture of rac-trans-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1-amine hydrochloride (90.00 mg, 289.95 μmol, 1.0 equiv) and DIPEA (74.95 mg, 579.90 μmol, 2.0 equiv) in DCM (6 mL) was added compound 7 (30 mg, 331.46 μmol, 1.14 equiv) at 0°C. The mixture was stirred at 0°C for 10 min. LCMS showed complete consumption of the starting material. MeOH (3 mL) was added dropwise. The reaction mixture was concentrated to give rac-trans-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide (100.00 mg, crude) as a yellow oil. LCMS: (M+H + :365.2.).

[0590] 6. Separation of racemic-trans-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide

[0591]

[0592] Racemic-trans-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide (100.00 mg, 274.39 μmol, 1.0 equiv) was separated by SFC (column: Phenomenex-Cellulose-2 (250 mm x 30 mm, 10 μm); conditions: 0.1% NH3H2O ​​EtOH, start B 40, end B 40, flow rate (mL / min) 80.) to give Example 24 (41.1 mg, 40.15% yield) as a yellow solid and Example 25 (47.1 mg, 47.10% yield) as a yellow solid.

[0593] Embodiment 24 Spectrum of:

[0594]

[0595] LCMS (M+H + :365.2).HPLC:(purity:97.70%).SFC(purity:94.99%). 1 H NMR: (400MHz, METHANOL-d4)δ=8.68-8.62(m,1H),8.13-7.92(m,2H),6.95-6.68(m,2H),6.28-6.12(m ,1H),5.84-5.70(m,1H),5.46-5.05(m,1H),4.17-3.75(m,4H),3.11-2.82(m,3H),2.40-1.41(m,9H).

[0596] Embodiment 25 Spectrum of:

[0597]

[0598] LCMS: (M+H + :365.3).HPLC:(purity:100.00%).SFC:(purity:99.52%). 1 H NMR: (400MHz, METHANOL-d4)δ=8.71-8.61(m,1H),8.16-7.95(m,2H),6.98-6.70(m,2H),6.28-6.14(m ,1H),5.84-5.70(m,1H),5.46-5.05(m,1H),4.11-3.72(m,4H),3.13-2.86(m,3H),2.33-1.49(m,9H).

[0599] 7. Preparation of racemic-cis-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1-amine hydrochloride

[0600]

[0601] To a mixture of racemic-cis-methyl(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)carbamic acid tert-butyl ester (200 mg, 0.487 mmol, 1.0 equiv) in DCM (2 mL) was added EtOAc (4 M, 8.00 mL) containing HCl. The mixture was stirred at 25 °C for 1 hour. LCMS showed that the starting material was completely consumed and a peak with the desired MS was detected. The reaction mixture was concentrated to give racemic-cis-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1-amine hydrochloride (120 mg, crude) as a yellow solid, which was used directly in the next step. LCMS: (M+H + :311.2).

[0602] 8. Preparation of racemic-cis-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide

[0603]

[0604] To a mixture of rac-cis-N-methyl-3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexane-1-amine hydrochloride (120 mg, 0.386 mmol, 1.0 equiv) and DIPEA (149.90 mg, 1.16 mmol, 3.0 equiv) in DCM (10 mL) at 0°C was added acryloyl chloride (38.49 mg, 0.425 mmol, 1.0 equiv). The mixture was stirred at 0°C for 2 min. LCMS showed complete consumption of the starting material and a peak with the desired MS was detected. MeOH (1 mL) was added dropwise. The resulting mixture was stirred at 25°C for 10 min. The solvent was removed to give crude rac-cis-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide (102 mg, crude) as a yellow oil. LCMS: (M+H + :365.2).

[0605] 9. Separation of cis-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide

[0606]

[0607] Racemic-cis-N-methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)cyclohexyl)acrylamide (102 mg, 0.280 mmol, 1.0 equiv) was separated by SFC (column: DAICEL CHIRALPAK IG (250 mm x 30 mm, 10 μm); conditions: 0.1% NH3H2O ​​EtOH, start B 50%, end B 50%, gradient time (min), 100% B hold time (min), flow rate (mL / min) 80) to give Example 26 (37.2 mg, 36.47% yield) as a white solid and Example 27 (33.4 mg, 32.75% yield) as a light yellow solid.

[0608] Embodiment 26 Spectrum of:

[0609]

[0610] LCMS: (M+H + :365.2).SFC:(ee:99.57%).HPLC:(purity:100%). 1 H NMR: (400MHz, METHANOL-d4) δ = 8.64 (d, J = 4.0Hz, 1H), 8.14 (s, 1H), 8.05-7.92 (m, 2H), 6.99 (s, 1H), 6.93-6.66 (m, 1H), 6.23-6.16 (m, 1H) ),5.74(d,J=10.8Hz,1H),4.41-4.39(m,1H),3.95(s,3H),3.41-3.38(m,1H),3.09-2.91(m,3H),2.32-1.89(m,4H),1.86-1.61(m,4H).

[0611] Embodiment 27 Spectrum of:

[0612]

[0613] LCMS: (M+H + :365.3).SFC:(ee:98.44%).HPLC:(purity:100%). 1H NMR: (400MHz, METHANOL-d4) δ = 8.65 (d, J = 4.0Hz, 1H), 8.15 (s, 1H), 8.05-7.92 (m, 2H), 6.99 (s, 1H), 6.93-6.66 (m, 1H), 6.23-6.16 (m, 1H) ),5.74(d,J=10.8Hz,1H),4.41-4.39(m,1H),3.95(s,3H),3.41-3.38(m,1H),3.09-2.91(m,3H),2.32-1.89(m,4H),1.86-1.61(m,4H).

[0614] Embodiment 28 .N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)acrylamide

[0615]

[0616] 1. Preparation of 6-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenyl)pyrazolo[1,5-a]pyrazine

[0617]

[0618] 4-Chloro-6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine (150 mg, 641.97 umol), (3-nitrophenyl)boronic acid (215 mg, 1.29 mmol), Pd(dppf)Cl2 (15 mg, 20.50 umol), K2CO3 (250 mg, 1.81 mmol) and EtOH (3 mL) were added to an 8 mL vial, which was sealed and heated to 85°C for 2 hours, then analyzed by LCMS, showing complete consumption of the starting material. The reaction was cooled to room temperature.

[0619] The reaction mixture was diluted with 5mL EtOH and stirred at 40 ° C for 30 minutes, then filtered through a 0.2um syringe filter. The filtrate was analyzed by LCMS, showing that only traces of the desired product were present. The EtOH filtrate was discarded. 10mL DCM was added to the remaining solid, which completely dissolved all materials. The DCM filtrate was concentrated to obtain the desired product 6- (1- methylpyrazole -4- bases) -4- (3- nitrophenyl) pyrazolo [1,5-a] pyrazine (300mg, 936.61umol, 145.90% yield) in a tan solid state. LCMS: (M+H + :321.1). 1H NMR(500MHz,DMSO-d6)δppm 8.86(t,J=1.83Hz,1H)8.59(dd,J=7.94,1.22Hz,1H)8.42-8.47(m,1H)8.37(s,1H) 8.27 (d, J = 2.44Hz, 1H) 8.14 (s, 1H) 7.92 (s, 1H) 7.25 (d, J = 2.44Hz, 1H) 3.92 (s, 3H).

[0620] 2. Preparation of 3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)aniline

[0621]

[0622] Pd(OH)2 / C (125 mg, 178.02 umol, 20% purity) and 3:1 EtOAc:EtOH (8 mL) were added to a 30 mL vial containing 6-(1-methylpyrazol-4-yl)-4-(3-nitrophenyl)pyrazolo[1,5-a]pyrazine (200 mg, 624.40 umol). This mixture was purged with H2 for 15 minutes and then stirred at 40 °C under a H2 balloon for 1 hour. The reaction was analyzed by LCMS, showing complete conversion to the desired product. The H2 balloon was removed.

[0623] The reaction was filtered through celite and rinsed with 25 mL 3:1 EtOAc:EtOH. The filtrate was concentrated to dryness to give a light yellow solid 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]aniline (175 mg, 602.78 umol, 96.54% yield). LCMS: (M+H + :291.1). 1 H NMR(500MHz,DMSO-d6)δppm 9.09(d,J=1.22Hz,1H)8.31(s,1H)8.17(d,J=2.44Hz,1H)8.10(s,1H)7.36(t,J=1.83Hz,1H)7. 24(d,J=14.04Hz,2H)7.09(dd,J=2.44,1.22Hz,1H)6.74-6.79(m,1H)5.35(s,2H)3.91(s,3H).

[0624] 3. Preparation of N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)acrylamide

[0625]

[0626] DCM (5 mL) and DIPEA (148.40 mg, 1.15 mmol, 200 uL) were added to a 30 mL vial containing 3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-yl]aniline (175 mg, 602.78 umol) and stirred at room temperature for 5 minutes. The mixture was cooled on a dry ice / acetone bath for 10 minutes, and then acryloyl chloride (54.56 mg, 602.78 umol, 48.97 uL) was added. The reactants were warmed to room temperature and stirred for another 15 minutes.

[0627] The reactant was purified by silica gel column chromatography (12 g, heptane to 3:1 EtOAc: EtOH). The desired fractions were collected and concentrated to give a white solid N-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]phenyl]prop-2-enamide (180 mg, 512.24 umol, 84.98% yield, 98% purity). LCMS: (M+H + :345.1). 1 H NMR(600MHz,DMSO-d6)δppm 10.39(s,1H)9.15(s,1H)8.50-8.59(m,1H)8.30-8.37(m,1H)8.19-8.26(m,1H)8.09-8.14(m,1H)7.81-7.93( m,2H)7.52-7.64(m,1H)7.15-7.24(m,1H)6.44-6.54(m,1H)6.29-6.39(m,1H)5.76-5.87(m,1H)3.93(s,3H).

[0628] Embodiment 29 .N-Methyl-N-(3-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)phenyl)acrylamide

[0629]

[0630] To the 30mL bottle containing N-[3-[6-(1-methylpyrazole-4-yl)pyrazolo[1,5-a]pyrazine-4-yl]phenyl]prop-2-eneamide (130mg, 377.50umol), add THF (5mL) and iodomethane (130mg, 915.89umol, 57.02uL), it is stirred at room temperature for 5 minutes, then potassium tert-butoxide (1M, 750uL) is added dropwise. Make reactant stir 15 minutes, then analyze by LCMS, display is completely converted into required product. Reactant is diluted with 10mL water and extracted with 3x10mL EtOAc. The organic layer merged is concentrated to dryness, then by silica gel column chromatography (12g, heptane to 3:1EtOAc:EtOH) purification. The desired fractions were collected and concentrated to give yellow foam solid N-methyl-N-[3-[6-(1-methylpyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]phenyl]prop-2-enamide (105 mg, 287.11 umol, 76.06% yield, 98% purity). LCMS: (M+H + :359.1). 1 H NMR(500MHz,DMSO-d6)δppm 9.19(s,1H)8.35(s,1H)8.22(d,J=2.44Hz,1H)8.13(s,2H)8.00(s,1H)7.7 0(t,J=7.94Hz,1H)7.50-7.56(m,1H)7.17(dd,J=2.44,1.22Hz,1H)6.21(br s,2H)5.59-5.68(m,1H)3.91(s,3H)3.35-3.39(m,3H).

[0631] Examples 30 and 31 :(R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepan-1-yl)prop-2-en-1-one and (S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepan-1-yl)prop-2-en-1-one

[0632]

[0633] 1. Synthesis of tert-butyl 4-((methylsulfonyl)oxy)azepane-1-carboxylate

[0634]

[0635] TEA (201 mg, 1.99 mmol) was added dropwise to an ice-cold solution of tert-butyl 4-hydroxyazepane-1-carboxylate (214 mg, 0.994 mmol) in DCM (9.5 mL) under N2. MsCl (168 mg, 1.47 mmol) was added thereto at 0 ° C and the resulting solution was stirred at 0 ° C for 2 h. The mixture was quenched by adding water (10 mL) and the mixture was extracted with DCM (20 mL x 3). The combined organics were washed with brine (10 mL), dried (MgSO4) and evaporated to dryness in vacuo to give tert-butyl 4-((methylsulfonyl)oxy)azepane-1-carboxylate (0.326 g, yield: 112%) as a colorless oil. ESI-MS (M+Na) + :316.0.

[0636] 2. Synthesis of tert-butyl 4-(acetylthio)azepane-1-carboxylate

[0637]

[0638] To a room temperature solution of tert-butyl 4-((methylsulfonyl)oxy)azepane-1-carboxylate (0.163 g, 0.52 mmol) in DMF (5.5 mL) was added potassium thioacetate (112 mg, 0.980 mmol) and the mixture was stirred overnight at 80 ° C under nitrogen. The mixture was quenched by adding water (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine, dried (Na2SO4) and concentrated in vacuo. The residue was purified by silica gel chromatography (0-100% EtOAc / heptane) to give tert-butyl 4-(acetylthio)azepane-1-carboxylate (0.105 g, yield: 74%) as an orange oil. ESI-MS (M+Na) + :296.1.

[0639] 3. Synthesis of tert-butyl 4-mercaptoazepane-1-carboxylate

[0640]

[0641] To the room temperature solution of 4-(acetylthio)azepane-1-formic acid tert-butyl esters (0.104g, 379μmol) in MeOH (6mL), sodium methoxide (120uL, 0.52mmol, 4.37M) is added and the mixture is stirred for 1h at room temperature under nitrogen. The mixture is diluted with water (10mL) and extracted with EtOAc (20mL x 3). The organic matter merged is washed with saturated sodium chloride solution, dried (Na2SO4) and evaporated to dryness in a vacuum to obtain 4-mercaptoazepane-1-formic acid tert-butyl esters (83mg, yield: 95%) in an orange oil. 1 H NMR (400MHz, CDCl3) δ3.47-3.62(m,1H),3.15-3.47(m,3H),3.00-3.13(m,1H),1.58-2.19(m,7H),1.47(s,9H).

[0642] 4. Synthesis of tert-butyl 4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepane-1-carboxylate

[0643]

[0644] To 4-mercaptoazepine-1-carboxylic acid tert-butyl ester (83mg, 0.360mmol) in THF (5mL) stirred 0 DEG C of solution, sodium hydride (43mg, 1.1mmol, 60% purity) is added and the mixture is stirred at 0 DEG C for 0.5h, then 4-chloro-6-(1-methyl-1H-pyrazole-4-yl) pyrazolo [1,5-a] pyrazine (101mg, 0.433mmol) is added and the resulting mixture is stirred at room temperature for 2h. The reactant is stopped by adding water (2mL) and extracted with EtOAc (3x5mL). The combined organic matter is washed with saturated sodium chloride solution, dried (Na2SO4) and evaporated to dryness in a vacuum. The residue is purified twice by silica gel chromatography, first using 0-100% 3: 1EtOAc-EtOH / heptane as eluent, then using 0-10% MeOH / methyl chloride as eluent. The material was repurified using reverse phase HPLC (Waters XSelect CSH C18, 5 μm, 50 mm×100 mm column, using mobile phases H 2 O (A) and MeCN (B) and a gradient of 10-90% B (0.1% TFA final v / v % modifier), flow rate of 30 mL / min) to give tert-butyl 4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepane-1-carboxylate (76 mg, yield: 49%) as a colorless oil. ESI-MS (M+H)+ :429.2.

[0645] 5. Synthesis of 4-(azepan-4-ylthio)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine

[0646]

[0647] TFA (60 mg, 530 μmol, 40 uL) was added to a solution of tert-butyl 4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine-4-yl)thio)azepane-1-carboxylate (76 mg, 0.180 mmol) in HFIPA (1 mL) and the solution was stirred at room temperature for 1 h. The reaction mixture was evaporated to dryness, diluted with DCM, and washed with saturated sodium bicarbonate solution. The aqueous solution was re-extracted with a mixture of CHCl3 / IPA (8 to 1 v / v ratio, 3 times). The combined organics were dried (MgSO4) and evaporated to dryness in vacuo to give 4-(azepan-4-ylthio)-6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazine (52 mg, yield: 90% yield) as a colorless film, which was used without further purification. ESI-MS (M+H) + :329.1.

[0648] 6. Synthesis of (R)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepan-1-yl)prop-2-en-1-one and (S)-1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepan-1-yl)prop-2-en-1-one

[0649]

[0650] DCM (1mL) and triethylamine (80mg, 0.79mmol) were added to a 20mL vial containing 4-(azepan-4-ylthio)-6-(1-methyl-1H-pyrazole-4-yl)pyrazolo[1,5-a]pyrazine (52mg, 0.160mmol) in sequence. The mixture was stirred at room temperature for 5min and then cooled to 0°C. Acryloyl chloride (21mg, 0.240mmol) was added dropwise and the reactant was slowly warmed to room temperature. After stirring at room temperature for 1h, the reaction mixture was diluted with DCM and washed with saturated sodium bicarbonate solution. The organic layer was collected. The water layer was extracted again with 2x DCM. The combined organics were dried (MgSO4) and evaporated to dryness in a vacuum to obtain a light yellow film. This material was purified by silica gel chromatography (0-100% 3:1 EtOAc-EtOH / heptane) to give racemic 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepan-1-yl)prop-2-en-1-one (30 mg, yield: 49%) as a colorless film. 1-(4-((6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl)thio)azepan-1-yl)prop-2-en-1-one (25 mg) was separated by chiral SFC (CHIRALPAK AD-H 30x250 mm, 5 um, 45% MeOH, no modifier, in CO2, flow rate: 100 mL / min, ABPR 120 bar, MBPR 40 psi, column temperature 40°C) to provide:

[0651] *Peak 1, Example 30, E1 (8.6 mg, 34%). 1H NMR (400 MHz, MEOH-d4) δ 8.55 (s, 1H), 8.08-8.18 (m, 1H), 7.99 (s, 1H), 7.94 (t, J = 2.01 Hz, 1H), 6.82 (ddd, J = 10.54, 15.18, 16.69 Hz, 1H), 6.72-6.75 (m, 1H), 6.30 (ddd, J = 2.01, 11.29, 16.82 Hz, 1H) ,5.78(ddd,J=2.01,10.54,16.56Hz,1H),4.25-4.45(m,1H),3.98(d,J=4.27Hz,3H),3.83-3.93( m,1H),3.57-3.83(m,3H),2.37-2.55(m,1H),2.17-2.28(m,1H),1.88-2.17(m,4H).ESI-MS(M+H) + :383.1.

[0652] *Peak 2, Example 31, E2 (9.2 mg, 37%). 1H NMR (400 MHz, MEOH-d4) δ 8.55 (s, 1H), 8.09-8.17 (m, 1H), 7.99 (s, 1H), 7.94 (t, J = 2.01 Hz, 1H), 6.82 (ddd, J = 10.54, 15.12, 16.75 Hz, 1H), 6.72-6.76 (m, 1H), 6.31 (ddd, J = 2.01, 11.11, 16.75 Hz, 1H) ,5.78(ddd,J=2.13,10.54,16.69Hz,1H),4.26-4.45(m,1H),3.98(d,J=4.27Hz,3H),3.83-3.93( m,1H),3.56-3.83(m,3H),2.39-2.54(m,1H),2.18-2.28(m,1H),1.87-2.18(m,4H).ESI-MS(M+H) + :383.1.

[0653] D. In vitro analysis

[0654] In vitro BTK kinase assay: Btk-PolyGAT-LS assay

[0655] The purpose of BTK in vitro analysis is to determine the potency of the compound for BTK by measuring IC50. In the presence of active BTK enzyme (Upstate 14-552), ATP and inhibitors, the compound inhibition is measured after monitoring the phosphorylation amount of fluorescein-labeled polyGAT peptide (Invitrogen PV3611). BTK kinase reaction is carried out in a black 96-well plate (costar 3694). In a typical analysis, a 24pL aliquot of kinase buffer (10mM Tris-HCl pH 7.5, 10mM MgCl2, 200μΜ Na3PO4, 5mM DTT, 0.01% Triton X-100 and 0.2mg / mL casein) containing ATP / peptide master mix (final concentration; ATP 10μΜ, polyGAT100nM) is added to each well. Next, 1pL of 4 times 40X compound titration in 100% DMSO solvent was added, followed by 15uL of 1X kinase buffer containing BTK enzyme mixture (final concentration of 0.25nM). The analyte was incubated for 30 minutes and then stopped with 28pL of 50mM EDTA solution. An aliquot (5uL) of the kinase reaction was transferred to a low-capacity white 384-well plate (Coming 3674), and 5pL of 2X detection buffer (Invitrogen PV3574, containing 4nM Tb-PY20 antibody, Invitrogen PV3552) was added. The plate was covered and incubated at room temperature for 45 minutes. Time-resolved fluorescence (TRF) was measured on Molecular Devices M5 (332nm excitation; 488nm emission; 518nm fluorescein emission). IC50 values ​​were calculated using four-parameter fitting, 100% enzyme activity was determined from the DMSO control and 0% activity was determined from the EDTA control.

[0656] Table 1 shows the activity of selected exemplary compounds of the invention in an in vitro Btk kinase assay, wherein each compound number corresponds to the example number in Examples 1-31. Indicates IC 50 Greater than 1 μM and equal to or less than 10 μM. Indicates IC 50 Greater than 10 nM and equal to or less than 1 μM (10 nM < IC 50 ≤1μM). Indicates IC 50 Greater than 1 nM and equal to or less than 10 nM (1 nM <IC 50 ≤10nM). Indicates that the IC50 is less than 1 nM.

[0657] Table 1

[0658]

[0659]

[0660] In vitro whole blood CD69 analysis

[0661] Human heparinized venous blood from healthy donors was aliquoted into 96-well plates and "added" to serial dilutions of Formula I compounds in DMSO or DMSO without drugs. The final concentration of DMSO in all wells was 0.1%. The plate was incubated at 37°C for 30min. The drug-containing samples were stimulated with 0.1 μg / mL mouse anti-human IgD-dextran (1A62) or 20 μg / mL polyclonal rabbit F(ab')2 anti-human IgD. Phosphate buffered saline (PBS) was added to the negative control unstimulated sample and the plate was incubated overnight (18 to 22 hours) at 37°C. Cells were stained with anti-CD19 and anti-CD69 antibodies conjugated with fluorescent dyes. Red blood cells were removed by hypotonic dissolution using a dissolving / fixing solution and the remaining cells were fixed, and then the remaining cells were analyzed by flow cytometry. CD19+B cells were gated and CD69 expression was analyzed. The percentage of B cells expressing CD69 was plotted versus the log10 of drug concentration and a best fit curve (variable Hill slope) was generated to obtain IC50 values.

[0662] Table 2 shows the activity of selected exemplary compounds of the invention in the in vitro whole blood CD69 assay, wherein each compound number corresponds to the example number shown in Examples 1-31 herein. Indicates IC 50 Greater than 10μM. Indicates IC 50 Greater than 1 μM and equal to or less than 10 μM (1 μM <IC 50 ≤10μM). Indicates IC 50 Less than 1μM.

[0663] Table 2

[0664]

[0665]

[0666] nt: Not measured.

Claims

1. A compound represented by formula (I): or a pharmaceutically acceptable salt thereof, wherein: X 0 N, X 1 C, X 2 is N and X 4 N; X 0 CR 0 , X 1 C, X 2 is N and X 4 N; X 0 CR 0 , X 1 N, X 2 is C and X 4 N; X 0 CR 0 , X 1 N, X 2 is C and X 4 is CH; or X 0 CR 0 , X 1 C, X 2 is N and X 4 for CH; R 0 is H, halo, -CH3, halomethyl, cyclopropyl or CN; Het is phenyl, 5-6 membered heteroaryl or N-(C1-C1 alkyl)pyridinone; R 1 is H or C1-C3 alkyl, C1-C3 alkoxy, C1-C3 haloalkyl, C3-C6 cycloalkyl or 4-7 membered monocyclic oxygen-containing heterocycle; X 3 Does not exist, -S-, -SO2-, CR 3a R 3b , -C(=O)- or -(C=O)-NH-*, where * indicates connection to R 2 point; R 3a and R 3b Each independently is H or halogen, wherein R 3a and R 3b At least one of is not H; When X 3 Does not exist, -S-, -SO2-, CR 3a R 3b or -(C=O)-NH-*, R 2 is bonded to X through a ring carbon atom 3 ("C-linked") 4-12 membered monocyclic or bicyclic nitrogen-containing heterocyclic ring bonded to X via a ring nitrogen atom 3 ("N-linked"), an 8-12 membered bicyclic nitrogen-containing heterocycle, a 4-7 membered monocyclic oxygen-containing heterocycle, a phenyl group, or a 3-12 membered monocyclic or bicyclic carbocyclic group, wherein R 2 The 4-7 membered monocyclic oxygen-containing heterocyclic ring, the phenyl group and the 3-12 membered monocyclic or bicyclic carbonyl group represented by R are each 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R 2 The C-linked 4-12-membered monocyclic or bicyclic nitrogen-containing heterocyclic ring represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 and substituted by a group represented by R 2 The N-linked 8-12-membered bicyclic nitrogen-containing heterocycle represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; When X 3 When it does not exist, R 2 It can also be represented by formula (A): When X 3 When -C(=O)-, R2 is bonded to X through a ring nitrogen atom. 3 ("N-linked"), a 4-12 membered monocyclic or bicyclic nitrogen-containing heterocycle, a 4-7 membered monocyclic oxygen-containing heterocycle, a phenyl group, or a 3-12 membered monocyclic or bicyclic carbocyclic group, wherein R 2 The 4-7 membered monocyclic oxygen-containing heterocyclic ring, the phenyl group and the 3-12 membered monocyclic or bicyclic carbonyl group represented by R are each 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R 2 The N-linked 4-12-membered monocyclic or bicyclic nitrogen-containing heterocyclic ring represented by R 4 A group represented by R is C-substituted and optionally further substituted with one or two 10 The group represented by is substituted; R 4 for R 5 for R 6 is H, C1-C3 alkyl, C1-C3 haloalkyl, N(R a )2 or CH2N(R a )2, where each R a are independently H or methyl; R 6’ is H, C1-C3 alkyl or C1-C3 haloalkyl; R 7 is H, C1-C2 alkyl or C1-C2 fluoroalkyl; Each R 10 Independently F or C 1-3 alkyl; R 11 H or N(R 12 )2; Each R 12 are independently H or C1-C3 alkyl; R 13 CN or F; n is 0 or 1; p is 1 or 2; and q is 1 or 2.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein R 11 For H.

3. The compound of claim 1, wherein the compound is represented by one of the following structural formulas: or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is represented by one of the following structural formulas: or a pharmaceutically acceptable salt thereof, wherein R 3a and R 3b are each independently H or halogen, and R 3a and R 3b At least one of them is not H.

5. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein R 0 is H, Cl, F or -CH3; and R 3a and R 3b Each is F.

6. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 5, wherein X 3 Does not exist, -S-, -SO2-, CR 3a R 3b or -(C=O)-NH-*, and R 2 is bonded to X through a ring carbon atom 3 ("C-linked") 4-9 membered monocyclic or bicyclic nitrogen-containing heterocyclic ring, bonded to X via a ring nitrogen atom 3 ("N-linked") 8-9 membered bicyclic nitrogen-containing heterocycle, phenyl or 4-6 membered monocyclic carbocyclic group, wherein R 2 The phenyl group and the 4-6-membered monocyclic carbonyl group represented by R are each 4 and optionally further substituted with one or two groups represented by R 10 The group represented by R 2 The C-linked 4-9-membered monocyclic or bicyclic nitrogen-containing heterocyclic ring represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 and substituted by a group represented by R 2 The N-linked 8-9-membered bicyclic nitrogen-containing heterocycle represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented is substituted.

7. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein: R 2 is selected from cyclobutyl, cyclopentyl, cyclohexyl and phenyl, each of which is represented by R 4 and optionally further substituted with one or two groups represented by R 10 or R 2 is selected from the group consisting of azepanyl, azetidinyl, 9-azabicyclo[3.3.1]nonyl, 2-azabicyclo[2.2.2]octyl, 8-azabicyclo[3.2.1]octyl, 2,7-diazaspiro[4.4]nonane, octahydrocyclopenta[c]pyrrolyl, octahydro-1H-pyrrolo[3,4-c]pyridine, piperidinyl, tetrahydropyridinyl and pyrrolidinyl, each of which is represented by the radical R 5 The group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented is substituted.

8. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from: as well as where m is 0, 1, or 2, and Indicates connection to X 3 or a bond to ring A.

9. The compound according to claim 6 or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from: as well as in Indicates connection to X 3 or a bond to ring A.

10. The compound of claim 1, wherein the compound is represented by the following structural formula: or a pharmaceutically acceptable salt thereof.

11. The compound according to claim 10 or a pharmaceutically acceptable salt thereof, wherein R 2 is bonded to X through a ring nitrogen atom 3 ("N-linked") 4-7 membered monocyclic nitrogen-containing heterocyclic ring or 4-6 membered monocyclic carbocyclic ring, wherein R 2 The 4-6 membered monocyclic carbocyclic groups represented by 4 and optionally further substituted with one or two groups represented by R 10 and substituted by a group represented by R 2 The N-linked 4-7-membered monocyclic nitrogen-containing heterocycle represented by R 4 A group represented by R is C-substituted and optionally further substituted with one or two 10 The group represented is substituted.

12. The compound according to claim 11 or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from: where m is 0, 1, or 2, and represents the bond to the C(O)-ring A.

13. The compound according to claim 11 or a pharmaceutically acceptable salt thereof, wherein R 2 Selected from: in represents the bond to the C(O)-ring A.

14. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 12, wherein each R 10 are independently F, -CH3 or -CH2CH3.

15. The compound according to any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, in: R 4 for: R 5 for: R 6 is H or -CF3; R 6′ is -CH3; R 7 is H, -CH3 or -CH2CH3; n is 0 or 1, and Indicates connection to R 2 key.

16. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 15, wherein Het is a 5-membered heteroaryl group.

17. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, wherein Het is pyrazolyl.

18. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, wherein Het is: in represents the bond to ring A.

19. The compound according to claim 16 or a pharmaceutically acceptable salt thereof, wherein Het is: in represents the bond to ring A.

20. The compound or pharmaceutically acceptable salt thereof according to any one of claims 1 to 19, wherein R 1 It is C1-C3 alkyl, C1-C3 haloalkyl or C3-C6 cycloalkyl.

21. The compound of claim 20 or a pharmaceutically acceptable salt thereof, wherein R 1 It is -CH3, -CF3, cyclopropyl or cyclobutyl.

22. The compound of claim 1, wherein the compound is represented by one of the following structural formulas: or a pharmaceutically acceptable salt thereof, wherein: R 0 is H, F or -CH3; R 1 is -CH3, cyclopropyl or cyclobutyl; R 2a is bonded to X through a ring carbon atom 3 ("C-linked") 6-9 membered monocyclic or bicyclic nitrogen-containing heterocyclic ring, the monocyclic or bicyclic nitrogen-containing heterocyclic ring is connected by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; R 2b is bonded to X through a ring carbon atom 3 ("C-linked") 4-6 membered monocyclic nitrogen-containing heterocycle, the monocyclic nitrogen-containing heterocycle is connected by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; R 2c C 3-6 Cycloalkyl, wherein the cycloalkyl is represented by R 4 and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; R 2d is bonded to X through a ring carbon atom 3 ("C-linked") 4-7 membered monocyclic nitrogen-containing heterocycle, the monocyclic nitrogen-containing heterocycle is connected by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 or C 3-6 Cycloalkyl, wherein the cycloalkyl is represented by R 4 and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; R 4 for: R 5 for: and R 6 It is H or CF3.

23. The compound of claim 22 or a pharmaceutically acceptable salt thereof, wherein: R 2a is 8-azabicyclo[3.2.1]octyl, octahydrocyclopenta[c]pyrrolyl or piperidinyl, each of which is represented by the 5 The group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; R 2b is azetidinyl or pyrrolidinyl, each of which is represented by R 5 The group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 The group represented by is substituted; R 2c is a cyclopentyl group, wherein the cyclopentyl group is represented by R 4 and optionally further substituted with one or two groups represented by R 10 and R 2d is an azepanyl group, wherein the azepanyl group is represented by R 5 A group represented by N-substituted and optionally further substituted with one or two groups represented by R 10 A group represented by R is substituted, or a cyclobutyl group, wherein the cyclobutyl group is substituted by R 4 and optionally further substituted with one or two groups represented by R 10 The group represented is substituted.

24. The compound of claim 22 or a pharmaceutically acceptable salt thereof, wherein: R 2a for R 2b for R 2c for and R 2d for where m is 0, 1, or 2, and Indicates connection to X 3 or a bond to ring A.

25. The compound of claim 22 or a pharmaceutically acceptable salt thereof, wherein: R 2a for R 2b for R 2c for and R 2d for Where R 10 is -CH3 or -CH2CH3, and Indicates connection to X 3 or a bond to ring A.

26. A pharmaceutical composition comprising the compound according to any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

27. A method of treating a condition responsive to inhibition of Bruton's tyrosine kinase in a subject, the method comprising administering to the subject an effective amount of a compound according to any one of claims 1 to 25 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 26.

28. The method of claim 27, wherein the disorder is an autoimmune disorder.

29. The method of claim 28, wherein the autoimmune disorder is rheumatoid arthritis.

30. The method of claim 28, wherein the autoimmune disorder is systemic lupus erythematosus.

31. The method of claim 27, wherein the condition is atopic dermatitis.

32. The method of claim 27, wherein the disorder is leukemia or lymphoma.